

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country.

Study No: MAG111539														
Title : A Single-Blind Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Repeat Doses of GSK249320 in Patients With Stroke														
<p>Rationale: Myelin-associated glycoprotein (MAG) is one of the key proteins known to inhibit neuronal regeneration when released from oligodendrocytes in conditions of neuronal injury, such as stroke. GSK249320 is a humanized monoclonal antibody (mAb) that binds with high specificity to MAG and antagonizes or neutralizes MAG-mediated inhibition and has been shown to improve functional recovery after stroke in pre-clinical models, possibly by promoting neuroregeneration and plasticity.</p> <p>This was the first study of GSK249320 in subjects with stroke and was designed to establish repeat dose safety and define the doses of GSK249320 to be used in further trials to evaluate its efficacy in improving clinical function in subjects recovering from stroke.</p> <p>The population enrolled into this study included subjects with measurable motor deficit post stroke as defined by National Institutes of Health Stroke Scale (NIHSS), infarct size and location of the stroke. In contrast with neuroprotection treatments which are administered within a few hours post stroke, treatment with GSK249320 was started within 24-72 hours of stroke in line with the pre-clinical package of efficacy data and the purported mechanism of action.</p>														
Phase: IIa														
Study Period: 08-July-2009 to 31-January-2011														
<p>Study Design: MAG111539 was a placebo-controlled, single-blind, multicentre, randomized study to investigate the safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of escalating repeat IV doses of GSK249320 in subjects with stroke. The study was also designed to collect serial data on several functional and neurophysiological outcome measures during the first 16 week period of recovery after stroke. While the study was single blind, all subjects, site staff (except for the pharmacist) and GlaxoSmithKline (GSK) staff were blinded to treatment.</p>														
<p>Centers: This multi-center study was conducted at 15 centers in 3 countries including 2 centers in Canada, 8 centers in Germany and 5 centers in the United States (US). Of the 15 centers, 10 centers enrolled subjects.</p>														
Indication: Stroke														
<p>Treatment: Three dose escalation cohorts were planned, with a 1:1 randomization ratio in cohort 1 (8 planned subjects on GSK249320 and 8 on placebo) and a 2:1 ratio in each of cohorts 2 and 3 (8 planned subjects on GSK249320 and 4 on placebo) for a total of 40 subjects enrolled. A Dose Escalation Committee (DEC) reviewed key safety data from a cohort before escalation to the next highest dosing cohort occurred.</p> <p>Investigational product was administered as an intravenous (IV) infusion via a programmable infusion pump. Each subject was to receive two IV doses 9 ± 1 days apart, where the first dose was administered 24-72 hours post stroke. Assessments extended to at least 16 weeks. Provision was made for subjects to remain in the study until circulating levels of GSK249320 fell to a threshold which was suitable to allow for testing of antibodies to GSK249320. The table below describes the maximum length of time subjects in each cohort could have remained in the study.</p> <table border="1"> <thead> <tr> <th>Cohort</th><th>Dose</th><th>Length of Observation Period</th></tr> </thead> <tbody> <tr> <td>1</td><td>1 mg/kg</td><td>126 days</td></tr> <tr> <td>2</td><td>5 mg/kg</td><td>175 days</td></tr> <tr> <td>3</td><td>15 mg/kg</td><td>210 days</td></tr> </tbody> </table>			Cohort	Dose	Length of Observation Period	1	1 mg/kg	126 days	2	5 mg/kg	175 days	3	15 mg/kg	210 days
Cohort	Dose	Length of Observation Period												
1	1 mg/kg	126 days												
2	5 mg/kg	175 days												
3	15 mg/kg	210 days												
<p>Objectives: Primary:</p>														

<ul style="list-style-type: none"> To evaluate the safety and tolerability of two repeat IV doses of GSK249320 in subjects with stroke
<p>Primary Endpoints:</p> <ul style="list-style-type: none"> Adverse events (AEs), vital signs, physical examination (including full neurological exam.), 12-lead electrocardiograms (ECGs), nerve conduction tests (NCTs), magnetic resonance imaging (MRI) and clinical laboratory tests.
<p>Secondary Endpoints:</p> <ul style="list-style-type: none"> Presence of antibodies to GSK249320 was assessed in serum samples using immunoelectro-chemiluminescent (ECL) assay. If antibodies were detected, subsequent assays were used to determine if they were of neutralizing type. PK parameters: AUC(0-τ), C_{max}, t_{max}, t_{1/2} after second dose, clearance, volume of distribution. Gait velocity, Berg Balance Scale (BBS), Fugl-Meyer (FM) Motor Assessment, Box and Blocks, grip strength (dynamometer), modified Rankin scale (mRS), Barthel, NIHSS, Montreal cognitive assessment (MoCA), geriatric depression scale (GDS), Transcranial Magnetic Stimulation (TMS), and MRI. To explore linear or non-linear relationships between exposure parameters and one or a combination of PD endpoints. Possible extension to a disease progression model, if feasible. Exploratory biomarker levels, such as: S100β.
<p>Statistical Methods: The sample size was based on safety, feasibility and the need to provide sufficient placebo-treated subjects to characterize functional and electrophysiological outcome measures in terms of variability and placebo response during the first 16 weeks after stroke. No sample size re-estimation was carried out.</p> <p>No formal interim analyses were performed. The decision to escalate to a higher dose was made by the DEC based on assessment of preliminary safety and PK data from the current dose (and the preceding doses, where applicable). The final planned analyses were performed after all subjects completed the study and after the database was frozen/unblinded. The database was frozen/unblinded on 12 May 2011.</p> <p>This study was designed to investigate the safety, tolerability and PK of repeat doses of GSK249320. No formal hypotheses were tested.</p> <p>An assessment of dose proportionality was made on AUC (0-∞), AUC(0-10d), and C_{max} using the Power Model. Mean change in gait velocity, BBS, FM Motor Assessment, Box and Blocks, grip strength, TMS (for each stimulation level), NIHSS and Barthel were analyzed using a repeated measures analysis. A mixed effect model was fitted, with treatment, visit, treatment by visit interaction and baseline as fixed effects. Visit was fitted on the repeated statement. Adjusted means for each treatment group and at each visit was summarized and plotted with 95% confidence intervals (CIs). Box and Blocks and grip strength also included the unaffected arm baseline as a covariate.</p> <p>The mRS was analyzed at each visit using Chi-Square test. Montreal Cognitive Assessment (MoCA) and Geriatric Depression Scale (GDS) at Day 90 were analyzed using analysis of covariance (ANCOVA) with treatment as the fixed effect and Day 5 score as a covariate. A further repeated measures analysis was performed on the mean change in gait velocity for subjects with a leg deficit and who completed the assessment per the protocol (i.e., walked at a comfortable pace). For this analysis the treatment group comparison was for GSK249320 (any dose) vs. placebo.</p> <p>The All Subjects Population was defined as all subjects who received at least one dose of study medication. This population was used for the reporting of all safety and PD data. The Pharmacokinetic (PK) Population was defined as subjects in the 'All Subjects' Population for whom a PK sample was obtained and analyzed. This population was used for the reporting of all PK data.</p>
<p>Study Population:</p> <p>Subjects eligible for inclusion in the study included those with</p> <ul style="list-style-type: none"> Confirmed diagnosis of stroke according to the World Health Organization definition and: <ul style="list-style-type: none"> Radiologically confirmed to be ischemic and supratentorial with a lesion diameter >15 mm in any direction or volume >4 cc, OR Radiologically confirmed intracerebral hemorrhage that is supratentorial, deep (blood must not directly contact cerebral cortex), with minimal or no intraventricular extension and with an Intracerebral Hemorrhage score of 0-2. Stroke onset within the last 24-72 hours.

- Total National Institute of Health Stroke Scale (NIHSS) score of 3-21.
- Upper and/or lower limb deficit defined as:
 - NIHSS motor arm score of 1-3 and palpable and observable voluntary extension or flexion of the fingers, and/or
 - NIHSS motor leg score of 1-3
- Males and females (child-bearing or non-child bearing potential), aged 18-90, inclusive.
- Reasonable likelihood of receiving standard rehabilitation therapy as indicated for the post stroke

Exclusion criteria included

- History of a previous symptomatic stroke within 3 months prior to study entry.
- Presence of significant disability prior to the current stroke. Significant disability was defined as having a pre-stroke Rankin score of >2.
- Subjects who were not alert or were unresponsive as defined by a score of 2 or 3 on the NIHSS Level of Consciousness question.
- Presence of significant depression, significant aphasia or other neurological or psychiatric disease likely to confound clinical evaluations.
- Presence of peripheral neuropathy or demyelinating disease.
- Evidence of other chronic co-morbid conditions or unstable acute systemic illnesses which, in the opinion of the investigator, could have shortened the subject's survival or limited his/her ability to complete the study.
- Planned participation in an investigational rehabilitation paradigm targeting stroke recovery.
- Pregnant or lactating females.
- Subjects considered unwilling or unable to comply with the procedures and study visit schedule outlined in the protocol.

Number of Subjects	Placebo	GSK2493 20 1 mg/kg	GSK2493 20 5 mg/kg	GSK2493 20 15 mg/kg	Total
Planned N	16	8	8	8	40
Dosed N	17	8	9	8	42
Completed n (%)	14 (82)	8 (100)	8 (89)	6 (75)	36 (86)
Total Number Subjects Withdrawn N (%)	3 (18)	0	1 (11)	2 (25)	6 (14)
Withdrawn due to Adverse Events n (%)	0	0	0	0	0
Withdrawn due to Lack of Efficacy n (%)	0	0	0	0	0
Withdrawn for Other Reasons n (%)					
Investigator discretion	0	0	0	1 (13)	1 (2)
Withdrew consent	3 (18)	0	1 (11)	1 (13)	5 (12)
Demographics					
Number of subjects included in All Subjects (safety) Population, n (%):	17 (100)	8 (100)	9 (100)	8 (100)	42 (100)
Number of subjects included in PK Population, n (%):	0	8 (100)	9 (100)	8 (100)	25 (60)
Mean Age in Years (SD)	67.6 (10.79)	62.1 (13.01)	63.9 (13.76)	59.3 (12.99)	64.2 (12.27)
Sex, n (%)					
Female	11 (65)	3 (38)	5 (56)	4 (50)	23 (55)
Male	6 (35)	5 (63)	4 (44)	4 (50)	19 (45)
Mean Weight in kg (SD)	76.59 (18.526)	87.24 (27.059)	69.44 (9.050)	84.28 (15.813)	78.55 (18.935)
White – White/Caucasian/ European Heritage	17 (100)	7 (88)	9 (100)	7 (88)	40 (95)
Primary Efficacy Results:					
The primary endpoint was safety, see "Safety Results" below.					
Secondary Outcome Variable(s):					
Results for secondary endpoints related to GSK249320 antibody formation, PK, PD, and biomarkers are presented below, following the primary safety endpoint results.					

Safety Results:

Adverse events (AE) were collected and recorded on the eCRF from the start of the GSK249320/placebo infusion through the last follow up visit for a subject. Serious adverse events (SAE) were collected and recorded on the eCRF from time of consent through the last follow up visit for a subject.

Adverse Events Reported in 2 or More Subjects (All Subjects Population)

	Placebo N=17	GSK249320 1 mg/kg N=8	GSK249320 5 mg/kg N=9	GSK249320 15 mg/kg N=8
Preferred Term	n (%)	n (%)	n (%)	n (%)
Any event	11 (65)	6 (75)	8 (89)	6 (75)
Insomnia	1 (6)	2 (25)	1 (11)	1 (13)
Constipation	2 (12)	2 (25)	1 (11)	0
Pyrexia	1 (6)	1 (13)	1 (11)	1 (13)
Diarrhoea	0	2 (25)	1 (11)	0
Hypokalaemia	1 (6)	1 (13)	1 (11)	0
Cerebrovascular accident	0	0	0	2 (25)
Headache	1 (6)	0	0	1 (13)
Ischemic stroke	1 (6)	0	1 (11)	0
Atrial fibrillation	1 (6)	0	2 (22)	0
Tachycardia	0	1 (13)	1 (11)	0
Arthralgia	1 (6)	0	0	1 (13)

Adverse Events by Maximum Intensity/Grade (All Subjects Population)

	Placebo N=17	GSK249320 1 mg/kg N=8	GSK249320 5 mg/kg N=9	GSK249320 15 mg/kg N=8
Preferred Term	n (%)	n (%)	n (%)	n (%)
Subjects with any AE	11 (65)	6 (75)	8 (89)	6 (75)
Mild	3 (18)	2 (25)	2 (22)	1 (13)
Moderate	6 (35)	3 (38)	5 (56)	4 (50)
Severe	2 (12)	1 (13)	1 (11)	1 (13)

Drug-Related Adverse Events (All Subjects Population)

	Placebo N=17	GSK249320 1 mg/kg N=8	GSK249320 5 mg/kg N=9	GSK249320 15 mg/kg N=8
Preferred Term	n (%)	n (%)	n (%)	n (%)
Any event	0	0	1 (11)	1 (13)
Cerebral infarction	0	0	0	1 (13)
Dysgeusia	0	0	1 (11)	0
Renal failure acute	0	0	0	1 (13)

Serious Adverse Events (All Subjects Population)

n (%) [n considered by the investigator to be related to study medication]

	Placebo N=17	GSK249320 1 mg/kg N=8	GSK249320 5 mg/kg N=9	GSK249320 15 mg/kg N=8
Preferred Term	n (%)	n (%)	n (%)	n (%)
Any event	3 (18)	1 (13)	3 (33)	3 (38)
Ischemic stroke	1 (6)	0	1 (11)	0
Cerebral infarction	0	0	0	1 (13) [1]
Cerebrovascular accident	0	0	0	1 (13)
Myocardial infarction	0	1 (13)	0	0
Tachycardia	0	0	1 (11)	0

Helicobacter infection	0	0	1 (11)	0
Peridiverticulitis	0	0	1 (11)	0
Failure to thrive	0	0	0	1 (13)
Depression	0	0	1 (11)	0
Renal failure acute	0	0	0	1 (13) [1]
Pulmonary oedema	0	0	1 (11)	0
Peripheral arterial occlusive disease	0	0	0	1 (13)
Epilepsy	1 (6)	0	0	0
Transient ischemic attack	1 (6)	0	0	0
Pyrexia	1 (6)	0	0	0
Post procedural complication	1 (6)	0	0	0
Fatal Serious Adverse Events (All Subjects Population)				
	Placebo N=17	GSK249320 1 mg/kg N=8	GSK249320 5 mg/kg N=9	GSK249320 15 mg/kg N=8
Preferred Term	n (%)	n (%)	n (%)	n (%)
Subject with fatal SAE, n (%)	0	0	0	0
Summary of All Events Common to Stroke (All Subjects Population)¹				
	Placebo N=17	GSK249320 1 mg/kg N=8	GSK249320 5 mg/kg N=9	GSK249320 15 mg/kg N=8
Preferred Term	n (%)	n (%)	n (%)	n (%)
Any event	11 (65)	6 (75)	7 (78)	4 (50)
Depression/mood disorder	4 (24)	3 (38)	3 (33)	1 (13)
Joint or soft tissue pain	2 (12)	2 (25)	4 (44)	1 (13)
Urinary tract infection	1 (6)	0	2 (22)	3 (38)
Bladder incontinence	1 (6)	0	2 (22)	2 (25)
Hemorrhagic transformation (asymptomatic or symptomatic)	2 (12)	2 (25)	1 (11)	0
Progression of stroke	3 (18)	0	1 (11)	1 (13)
Falls	1 (6)	2 (25)	1 (11)	0
Malnutrition	0	0	1 (11)	2 (25)
Bowel incontinence	2 (12)	0	0	1 (13)
Aspiration pneumonia	1 (6)	0	1 (11)	0
Dysarthria	1 (6)	1 (13)	0	0
Confusion	2 (12)	0	0	0
Seizures	2 (12)	0	0	0
Dysphagia	1 (6)	0	0	0
Limb edema	1 (6)	0	0	0
1. These events were collected during the physical exam. They were pre-defined events commonly occurring after stroke and generally associated with progression of stroke and were to be recorded by the Investigator but not listed as AEs or SAEs unless they were more severe than normally expected or if an investigator considered them related to investigational product				
Summary of Vital Signs (All Subjects Population)				
	Placebo N=17	GSK249320 1 mg/kg N=8	GSK249320 5 mg/kg N=9	GSK249320 15 mg/kg N=8
Treatment Group				
SYSTOLIC BLOOD PRESSURE (MMHG)				
Visit 1 – Pre-dose, n	17	8	9	8
Mean (SD)	145.3 (27.54)	151.6 (13.00)	142.0 (30.44)	138.6 (23.12)
Median	146.0	151.5	155.0	130.5
Median Range	93; 190	134; 177	89; 177	117; 178

Visit 1 – 15 mins post-dose, n	17	8	9	8
Mean (SD)	145.9(30.22)	146.3 (15.46)	134.3 (20.31)	143.5 (24.14)
Median	149.0	145.0	135.0	134.0
Median Range	95; 197	120; 169	110; 159	115; 181
Visit 1 – 30 mins post-dose, n	17	8	9	8
Mean (SD)	148.0 (27.47)	143.1 (21.73)	143.4 (26.53)	136.6 (23.93)
Median	146.0	141.5	152.0	134.0
Median Range	97; 208	112; 182	105; 181	109; 173
Visit 1 – 45 mins post-dose, n	17	8	9	7
Mean (SD)	147.5 (25.66)	144.3 (29.24)	142.0 (25.14)	142.7 (20.19)
Median	146.0	139.0	141.0	134.0
Median Range	93; 195	103; 195	109; 177	124; 178
Visit 1 – 1 hr post-dose, n	16	8	9	7
Mean (SD)	144.4 (26.69)	144.5 (29.26)	142.3 (27.65)	142.7 (23.58)
Median	142.0	141.5	140.0	138.0
Median Range	83; 208	101; 189	100; 190	110; 168
Visit 1 – 2 hrs post-dose, n	17	7	9	8
Mean (SD)	153.1 (32.25)	153.4 (24.71)	146.2 (27.32)	137.6 (29.74)
Median	145.0	155.0	145.0	138.0
Median Range	94; 217	112; 183	105; 184	99; 191
Visit 1 – 4 hrs post-dose, n	17	7	8	8
Mean (SD)	144.0 (28.37)	155.3 (19.51)	153.9 (27.60)	150.6 (35.60)
Median	144.0	155.0	158.5	143.5
Median Range	90; 205	122; 186	100; 193	97; 210
Visit 1 – 8 hrs post-dose, n	17	7	9	8
Mean (SD)	157.1 (28.95)	165.9 (19.13)	149.2 (32.82)	148.1 (28.12)
Median	157.0	172.0	160.0	138.0
Median Range	100; 223	142; 194	95; 185	116; 193
Visit 1 – 12 hrs post-dose, n	17	8	9	8
Mean (SD)	147.0 (26.16)	160.5 (23.32)	146.8 (37.99)	145.3 (30.89)
Median	150.0	156.0	160.0	144.0
Median Range	95; 192	128; 203	84; 192	99; 205
Visit 1 – 24 hrs post-dose, n	16	8	9	8
Mean (SD)	154.4 (17.57)	153.5 (19.65)	148.1 (33.22)	149.1 (27.78)
Median	153.5	147.0	145.0	145.0
Median Range	132; 191	137; 195	97; 217	116; 200
Visit 2, n	15	8	9	8
Mean (SD)	145.7 (13.20)	156.6 (20.17)	134.6 (23.54)	139.6 (20.32)
Median	147.0	154.5	138.0	137.0
Median Range	124; 166	131; 196	93; 165	115; 171
Visit 3 – Pre-dose, n	14	8	9	7
Mean (SD)	147.9 (27.04)	137.4 (25.09)	128.7 (23.81)	127.4 (27.67)
Median	137.0	137.5	125.0	121.0
Median Range	114; 200	107; 176	103; 162	95; 178
Visit 3 – 15 mins post-dose, n	14	8	9	7
Mean (SD)	146.2 (21.86)	136.1 (20.27)	135.4 (30.36)	126.3 (26.07)
Median	141.0	134.0	156.0	119.0
Median Range	120; 182	110; 172	100; 167	102; 164
Visit 3 – 30 mins post-dose, n	14	8	9	7
Mean (SD)	141.6 (24.89)	142.6 (21.65)	132.7 (24.98)	128.7 (27.80)
Median	135.5	143.0	142.0	119.0
Median Range	109; 187	108; 182	95; 165	106; 176
Visit 3 – 45 mins post-dose, n	14	8	9	7
Mean (SD)	142.8 (18.59)	143.1 (21.62)	129.4 (24.77)	127.9 (22.69)
Median	137.5	143.5	128.0	115.0

Median Range	117; 184	109; 181	92; 171	104; 163
Visit 3 – 1 hr post-dose, n	14	8	9	7
Mean (SD)	136.1 (16.43)	142.9 (26.04)	130.7 (26.32)	131.1 (28.17)
Median	136.5	143.0	129.0	123.0
Median Range	100; 161	110; 191	96; 175	98; 187
Visit 3 – 3 hrs post-dose, n	14	7	9	7
Mean (SD)	140.2 (17.99)	141.0 (21.93)	131.7 (23.18)	127.1 (21.47)
Median	135.5	148.0	132.0	130.0
Median Range	114; 184	115; 175	99; 176	96; 161
Visit 4, n	14	8	9	7
Mean (SD)	137.8 (21.15)	133.1 (18.15)	139.2 (23.65)	137.6 (18.49)
Median	137.5	137.0	137.0	148.0
Median Range	106; 183	105; 154	101; 185	111; 153
Visit 5, n	14	7	9	7
Mean (SD)	150.0 (24.19)	136.4 (13.94)	131.6 (24.50)	145.4 (21.49)
Median	148.0	137.0	125.0	147.0
Median Range	114; 181	119; 156	105; 173	112; 174
Visit 6, n	14	8	8	6
Mean (SD)	134.9 (18.88)	139.6 (13.41)	134.1 (38.42)	133.8 (15.38)
Median	130.5	134.0	128.5	140.5
Median Range	99; 161	124; 164	71; 188	106; 147
Visit 7, n	13	8	7	6
Mean (SD)	133.3 (20.63)	131.8 (12.03)	133.1 (25.83)	133.0 (17.32)
Median	134.0	131.5	124.0	124.5
Median Range	83; 163	109; 148	106; 171	120; 164
Early Withdrawal, n	3	0	0	0
Mean (SD)	136.3 (14.05)	0	0	0
Median	135.0	0	0	0
Median Range	123; 151	0	0	0
DIASTOLIC BLOOD PRESSURE (MMHG)				
Visit 1 – Pre-dose, n	17	8	9	8
Mean (SD)	76.1 (13.44)	76.8 (13.53)	70.6 (13.63)	74.9 (19.18)
Median	79.0	76.0	73.0	76.5
Median Range	49; 99	61; 99	56; 94	46; 101
Visit 1 – 15 mins post-dose, n	17	8	9	8
Mean (SD)	78.6 (14.54)	78.3 (12.98)	67.4 (17.30)	76.8 (16.15)
Median	80.0	81.0	75.0	76.5
Median Range	50; 105	61; 99	29; 84	54; 103
Visit 1 – 30 mins post-dose, n	17	8	9	8
Mean (SD)	79.6 (14.93)	77.6 (14.86)	71.4 (10.98)	74.8 (12.06)
Median	80.0	79.0	74.0	76.0
Median Range	48; 100	59; 100	50; 83	56; 93
Visit 1 – 45 mins post-dose, n	17	8	9	7
Mean (SD)	75.3 (15.63)	74.5 (18.91)	73.2 (15.94)	81.1 (10.78)
Median	76.0	70.0	75.0	83.0
Median Range	46; 98	48; 103	48; 98	64; 98
Visit 1 – 1 hr post-dose, n	16	8	9	7
Mean (SD)	79.3 (18.34)	82.9 (20.16)	72.2 (14.40)	75.3 (10.93)
Median	76.0	86.5	67.0	80.0
Median Range	49; 120	51; 107	56; 94	55; 87
Visit 1 – 2 hrs post-dose, n	17	7	9	8
Mean (SD)	80.1 (16.32)	81.4 (22.13)	78.2 (14.97)	75.6 (10.56)
Median	83.0	93.0	82.0	71.5
Median Range	49; 120	42; 100	60; 104	62; 91

Visit 1 – 4 hrs post-dose, n	17	7	8	8
Mean (SD)	72.8 (12.50)	90.3 (18.06)	81.0 (16.87)	80.8 (15.85)
Median	74.0	95.0	81.5	79.5
Median Range	52; 93	61; 111	59; 107	59; 103
Visit 1 – 8 hrs post-dose, n	17	7	9	8
Mean (SD)	77.4 (15.39)	89.4 (10.05)	78.9 (20.83)	77.8 (18.27)
Median	77.0	92.0	74.0	81.0
Median Range	51; 105	73; 104	50; 110	47; 96
Visit 1 – 12 hrs post-dose, n	17	8	9	8
Mean (SD)	76.7 (16.89)	83.4 (14.44)	76.8 (14.69)	75.4 (15.12)
Median	80.0	84.0	74.0	75.5
Median Range	47; 111	61; 104	57; 98	51; 98
Visit 1 – 24 hrs post-dose, n	16	8	9	8
Mean (SD)	80.0 (12.54)	74.8 (12.53)	78.6 (15.94)	79.8 (17.90)
Median	80.0	72.5	76.0	77.5
Median Range	54; 98	63; 98	62; 106	54; 109
Visit 2, n	15	8	9	8
Mean (SD)	81.5 (10.14)	81.3 (9.45)	76.3 (18.47)	78.3 (21.00)
Median	80.0	82.0	70.0	80.5
Median Range	65; 98	65; 96	65; 124	46; 109
Visit 3 – Pre-dose, n	14	8	9	7
Mean (SD)	81.2 (6.20)	78.8 (16.61)	74.6 (10.48)	71.9 (10.06)
Median	80.5	76.0	75.0	70.0
Median Range	72; 92	56; 104	60; 92	58; 88
Visit 3 – 15 mins post-dose, n	14	8	9	7
Mean (SD)	80.2 (6.27)	79.6 (12.29)	80.1 (17.35)	70.7 (15.20)
Median	79.0	78.5	87.0	75.0
Median Range	73; 96	65; 100	59; 102	47; 85
Visit 3 – 30 mins post-dose, n	14	8	9	7
Mean (SD)	81.6 (10.86)	75.0 (18.06)	74.6 (16.17)	71.0 (13.65)
Median	78.5	69.5	71.0	73.0
Median Range	68; 112	51; 99	55; 101	46; 86
Visit 3 – 45 mins post-dose, n	14	8	9	7
Mean (SD)	81.6 (8.39)	83.5 (14.41)	72.3 (12.72)	71.1 (13.36)
Median	82.0	87.5	73.0	69.0
Median Range	71; 92	60; 100	55; 86	52; 88
Visit 3 – 1 hr post-dose, n	14	8	9	7
Mean (SD)	79.6 (8.86)	76.5 (16.91)	74.2 (11.12)	70.7 (14.83)
Median	77.5	71.5	78.0	70.0
Median Range	70; 99	58; 103	60; 87	51; 90
Visit 3 – 3 hrs post-dose, n	14	7	9	7
Mean (SD)	80.0 (13.83)	82.9 (9.01)	80.0 (16.91)	72.1 (13.25)
Median	77.5	82.0	82.0	74.0
Median Range	64; 110	70; 96	55; 108	53; 91
Visit 4, n	14	8	9	7
Mean (SD)	76.9 (11.88)	76.0 (11.86)	85.1 (11.92)	77.9 (7.10)
Median	75.5	76.0	84.0	76.0
Median Range	60; 99	55; 93	67; 104	67; 87
Visit 5, n	14	7	9	7
Mean (SD)	83.9 (11.57)	81.0 (11.55)	77.2 (11.04)	84.1 (11.88)
Median	86.0	85.0	77.0	85.0
Median Range	63; 101	64; 94	62; 97	69; 102
Visit 6, n	14	8	8	6
Mean (SD)	79.9 (10.92)	81.6 (5.55)	77.6 (16.35)	74.7 (13.84)
Median	81.5	80.5	79.5	78.5

Median Range	62; 98	76; 93	52; 100	55; 88
Visit 7, n	13	8	7	6
Mean (SD)	78.8 (14.88)	77.6 (12.45)	81.6 (19.31)	76.7 (12.13)
Median	80.0	81.0	80.0	80.0
Median Range	50; 105	55; 89	52; 106	60; 91
Early Withdrawal, n	3	0	0	0
Mean (SD)	73.0 (10.58)	0	0	0
Median	69.0	0	0	0
Median Range	65; 85	0	0	0
HEART RATE (BEATS/MIN)				
Visit 1 – Pre-dose, n	17	8	9	8
Mean (SD)	76.1 (12.50)	86.0 (21.38)	74.0 (12.45)	80.1 (8.81)
Median	78.0	83.0	77.0	79.0
Median Range	53; 105	59; 130	50; 89	68; 94
Visit 1 – 15 mins post-dose, n	17	8	9	8
Mean (SD)	79.2 (14.00)	83.8 (21.63)	71.7 (15.88)	79.6 (10.57)
Median	80.0	80.5	71.0	78.5
Median Range	55; 105	61; 133	44; 94	62; 98
Visit 1 – 30 mins post-dose, n	17	8	9	8
Mean (SD)	80.1 (17.59)	87.1 (22.62)	75.0 (10.58)	78.4 (8.28)
Median	76.0	82.0	75.0	79.5
Median Range	54; 116	59; 133	59; 91	61; 90
Visit 1 – 45 mins post-dose, n	17	8	9	7
Mean (SD)	76.4 (15.23)	85.1 (22.20)	76.7 (16.02)	80.0 (12.03)
Median	74.0	82.5	74.0	77.0
Median Range	52; 115	58; 135	61; 112	63; 98
Visit 1 – 1 hr post-dose, n	16	8	9	6
Mean (SD)	76.7 (16.04)	84.1 (23.01)	74.3 (13.89)	76.7 (5.92)
Median	71.0	79.5	77.0	77.0
Median Range	55; 108	58; 134	53; 91	66; 83
Visit 1 – 2 hrs post-dose, n	17	7	9	8
Mean (SD)	75.4 (15.51)	76.0 (25.98)	81.1 (19.88)	79.9 (7.00)
Median	79.0	69.0	82.0	79.0
Median Range	47; 94	51; 130	55; 120	70; 92
Visit 1 – 4 hrs post-dose, n	17	7	9	8
Mean (SD)	79.8 (14.94)	81.1 (11.77)	71.4 (14.42)	77.9 (10.29)
Median	82.0	84.0	68.0	75.5
Median Range	55; 105	64; 98	52; 96	67; 95
Visit 1 – 8 hrs post-dose, n	17	7	9	8
Mean (SD)	73.5 (13.34)	70.4 (12.78)	75.3 (14.55)	74.5 (5.50)
Median	70.0	67.0	74.0	75.0
Median Range	51; 104	54; 86	56; 98	64; 81
Visit 1 – 12 hrs post-dose, n	17	8	9	8
Mean (SD)	71.8 (14.41)	70.1 (15.02)	70.1 (18.13)	71.4 (9.49)
Median	70.0	64.0	67.0	72.5
Median Range	50; 99	54; 91	45; 111	50; 80
Visit 1 – 24 hrs post-dose, n	16	8	9	8
Mean (SD)	75.1 (16.67)	70.4 (11.21)	70.8 (17.43)	80.9 (17.96)
Median	72.5	73.5	67.0	81.0
Median Range	50; 103	54; 86	53; 108	60; 115
Visit 2, n	15	8	9	8
Mean (SD)	74.0 (14.86)	77.5 (20.60)	71.4 (16.78)	76.8 (14.84)
Median	72.0	84.5	69.0	81.0
Median Range	50; 98	50; 99	55; 111	50; 98

Visit 3 – Pre-dose, n	14	8	9	7	
Mean (SD)	81.5 (17.45)	77.4 (20.32)	70.9 (10.51)	74.4 (17.72)	
Median	78.5	69.0	70.0	69.0	
Median Range	58; 125	58; 117	60; 90	55; 108	
Visit 3 – 15 mins post-dose, n	14	8	9	7	
Mean (SD)	74.4 (13.53)	78.6 (19.65)	76.4 (11.33)	72.9 (16.77)	
Median	72.5	75.0	76.0	71.0	
Median Range	54; 97	59; 115	61; 94	49; 101	
Visit 3 – 30 mins post-dose, n	14	8	9	7	
Mean (SD)	75.7 (19.48)	77.9 (18.13)	71.9 (11.93)	72.4 (18.88)	
Median	76.5	73.5	70.0	72.0	
Median Range	54; 126	61; 112	60; 91	46; 104	
Visit 3 – 45 mins post-dose, n	14	8	9	7	
Mean (SD)	77.4 (20.32)	77.5 (18.42)	74.3 (12.11)	74.3 (14.81)	
Median	79.5	74.0	68.0	73.0	
Median Range	52; 123	57; 112	62; 91	55; 102	
Visit 3 – 1 hr post-dose, n	14	8	9	7	
Mean (SD)	76.6 (19.39)	76.5 (14.22)	73.2 (11.92)	74.9 (14.04)	
Median	76.0	71.0	71.0	72.0	
Median Range	52; 126	62; 100	60; 94	55; 100	
Visit 3 – 3 hrs post-dose, n	14	7	9	7	
Mean (SD)	78.1 (17.49)	69.3 (10.16)	79.0 (13.70)	76.1 (15.99)	
Median	77.5	66.0	77.0	72.0	
Median Range	56; 119	58; 85	54; 101	55; 100	
Visit 4, n	14	8	9	7	
Mean (SD)	72.0 (12.23)	77.3 (20.76)	76.2 (8.51)	78.6 (13.95)	
Median	71.0	75.0	79.0	82.0	
Median Range	55; 97	52; 112	62; 90	59; 98	
Visit 5, n	14	7	9	7	
Mean (SD)	73.4 (12.73)	76.1 (11.98)	75.7 (8.00)	74.6 (10.34)	
Median	73.0	75.0	73.0	73.0	
Median Range	49; 90	59; 93	64; 88	56; 90	
Visit 6, n	14	8	8	6	
Mean (SD)	73.7 (13.95)	68.1 (12.14)	76.1 (9.96)	81.7 (17.24)	
Median	74.5	68.5	75.5	83.0	
Median Range	50; 98	49; 89	64; 88	61; 104	
Visit 7, n	13	8	7	6	
Mean (SD)	72.8 (14.25)	70.9 (8.04)	74.1 (8.40)	78.7 (22.37)	
Median	75.0	70.0	77.0	84.5	
Median Range	52; 101	61; 85	60; 84	49; 104	
Early Withdrawal, n	3	0	0	0	
Mean (SD)	78.7 (17.62)	0	0	0	
Median	81.0	0	0	0	
Median Range	60; 95	0	0	0	
Summary of ECG Findings (All Subjects Population)					
Visit	Impression	Placebo N=17	GSK249320 1 mg/kg N=8	GSK249320 5 mg/kg N=9	GSK249320 15 mg/kg N=8
		n (%)	n (%)	n (%)	n (%)
Visit 1 – Pre-dose, n		17	8	8	8
	Normal	6 (35)	3 (38)	5 (56)	3 (38)
	Abnormal, not clinically significant	9 (53)	4 (50)	3 (33)	5 (63)

	Abnormal, clinically significant	2 (12)	1 (13)	1 (11)	0
Visit 1 – 24 hrs Post-dose, n		15	7	8	8
	Normal	7 (47)	2 (29)	2 (25)	4 (50)
	Abnormal, not clinically significant	6 (40)	4 (57)	5 (63)	4 (50)
	Abnormal, clinically significant	2 (13)	1 (14)	1 (13)	0
Visit 2, n		14	8	9	8
	Normal	5 (36)	4 (50)	3 (33)	5 (63)
	Abnormal, not clinically significant	7 (50)	4 (50)	6 (67)	3 (38)
	Abnormal, clinically significant	2 (14)	0	0	0
Visit 3 – Pre-dose, n		14	7	9	7
	Normal	5 (36)	2 (29)	4 (44)	5 (71)
	Abnormal, not clinically significant	7 (50)	5 (71)	4 (44)	2 (29)
	Abnormal, clinically significant	2 (14)	0	1 (11)	0
Visit 3 – 3 hrs Post-dose, n		13	7	8	7
	Normal	6 (46)	2 (29)	3 (38)	4 (57)
	Abnormal, not clinically significant	5 (38)	4 (57)	4 (50)	3 (43)
	Abnormal, clinically significant	2 (15)	1 (14)	1 (13)	0
Visit 4, n		14	8	9	7
	Normal	6 (43)	1 (13)	4 (44)	6 (86)
	Abnormal, not clinically significant	7 (50)	6 (75)	4 (44)	1 (14)
	Abnormal, clinically significant	1 (7)	1 (13)	1 (11)	0
Visit 5, n		14	7	9	7
	Normal	6 (43)	4 (57)	5 (56)	4 (57)
	Abnormal, not clinically significant	7 (50)	3 (43)	3 (33)	3 (43)
	Abnormal, clinically significant	1 (7)	0	1 (11)	0
Visit 6, n		14	8	8	6
	Normal	5 (36)	1 (13)	4 (50)	4 (67)
	Abnormal, not clinically significant	8 (57)	7 (88)	4 (50)	2 (33)

	Abnormal, clinically significant	1 (7)	0	0	0
Visit 7, n		14	8	6	6
	Normal	6 (43)	1 (13)	3 (50)	3 (50)
	Abnormal, not clinically significant	7 (50)	7 (88)	3 (50)	3 (50)
	Abnormal, clinically significant	1 (7)	0	0	0
Early Withdrawal, n		2	0	0	0
	Normal	1 (50)	0	0	0
	Abnormal, not clinically significant	1 (50)	0	0	0
	Abnormal, clinically significant	0	0	0	0
Nerve Conduction Testing Values (All Subjects Population)					
Nerve Type/Visit	Impression	Placebo N=17	GSK249320 1 mg/kg N=8	GSK249320 5 mg/kg N=9	GSK249320 15 mg/kg N=8
		n (%)	n (%)	n (%)	n (%)
Motor					
Visit 2	Normal	11 (65)	7 (88)	7 (78)	4 (50)
	Abnormal, secondary to	4 (24)	1 (13)	2 (22)	4 (50)
	Not done	0	0	0	0
Visit 4	Normal	11 (65)	7 (88)	6 (67)	4 (50)
	Abnormal, secondary to	3 (18)	1 (13)	2 (22)	3 (38)
	Not done	0	0	0	0
Early withdrawal	Normal	0	0	0	0
	Abnormal, secondary to	2 (12)	0	0	0
	Not done	0	0	0	0
Sensory					
Visit 2	Normal	9 (53)	4 (50)	6 (67)	3 (38)
	Abnormal, secondary to	5 (29)	4 (50)	3 (33)	5 (63)
	Not done	1 (6)	0	0	0
Visit 4	Normal	12 (71)	5 (63)	7 (78)	3 (38)
	Abnormal, secondary to	2 (12)	3 (38)	1 (11)	4 (50)
	Not done	0	0	0	0
Early withdrawal	Normal	1 (6)	0	0	0
	Abnormal, secondary to	1 (6)	0	0	0
	Not done	0	0	0	0
MRI Results: Subjects with White Matter Changes (All Subjects Population)					
Subjects with White Matter Changes	Placebo N=17	GSK249320 1 mg/kg N=8	GSK249320 5 mg/kg N=9	GSK249320 15 mg/kg N=8	

	n (%)	n (%)	n (%)	n (%)
Day 10 compared to Day 1	9 (53)	5 (63)	5 (56)	2 (25)
Day 60 compared to Day 1	6 (35)	6 (75)	2 (22)	3 (38)
Day 60 compared to Day 10	5 (29)	5 (63)	1 (11)	3 (38)
MRI Review and Interpretation (All Subjects Population)				
MRI Comparison	Placebo N=17	GSK249320 1 mg/kg N=8	GSK249320 5 mg/kg N=9	GSK249320 15 mg/kg N=8
	n (%)	n (%)	n (%)	n (%)
Subjects with Demyelination				
Day 10 compared to Day 1				
Yes	1 (6)	0	3 (33)	0
No	13 (76)	8 (100)	6 (67)	7 (88)
Day 60 compared to Day 1				
Yes	0	0	0	0
No	14 (82)	8 (100)	9 (100)	6 (75)
Day 60 compared to Day 10				
Yes	0	0	0	0
No	14 (82)	8 (100)	9 (100)	6 (75)
During Study				
Yes	2 (12) ¹	0	3 (33)	0
No	13 (76)	8 (100)	6 (67)	7 (88)
Summary of Hematology Lab Values (Reference ranges available upon request)				
Treatment Group	Placebo N=17	GSK249320 1 mg/kg N=8	GSK249320 5 mg/kg N=9	GSK249320 15 mg/kg N=8
BASOPHILS (GI/L)				
Visit 1 – Pre-dose, n	16	8	8	8
Mean (SD)	0.033 (0.0214)	0.020 (0.0107)	0.019 (0.0136)	0.025 (0.0107)
Median	0.030	0.020	0.015	0.030
Median Range	0.00; 0.09	0.01; 0.04	0.00; 0.04	0.01; 0.04
Visit 1 – 24 hrs post-dose, n	14	7	9	7
Mean (SD)	0.031 (0.0207)	0.013 (0.0095)	0.019 (0.0117)	0.030 (0.0153)
Median	0.030	0.010	0.020	0.030
Median Range	0.00; 0.08	0.00; 0.03	0.00; 0.04	0.00; 0.05
Visit 2, n	13	7	9	8
Mean (SD)	0.031 (0.0180)	0.034 (0.0207)	0.011 (0.0078)	0.024 (0.0177)
Median	0.030	0.030	0.010	0.020
Median Range	0.00; 0.07	0.01; 0.07	0.00; 0.02	0.00; 0.05
Visit 3 – Pre-dose, n	13	8	9	7
Mean (SD)	0.026 (0.0171)	0.041 (0.0136)	0.024 (0.0181)	0.026 (0.0305)
Median	0.030	0.045	0.020	0.020
Median Range	0.00; 0.06	0.02; 0.06	0.00; 0.05	0.00; 0.09
Visit 3 – 3 hrs post-dose, n	12	7	8	7
Mean (SD)	0.036 (0.0281)	0.037 (0.0189)	0.025 (0.0120)	0.017 (0.0138)
Median	0.040	0.040	0.025	0.020
Median Range	0.00; 0.09	0.02; 0.07	0.01; 0.04	0.00; 0.03
Visit 4, n	13	8	8	7
Mean (SD)	0.036 (0.0176)	0.023 (0.0104)	0.025 (0.0120)	0.026 (0.0162)
Median	0.030	0.020	0.025	0.020
Median Range	0.01; 0.08	0.01; 0.04	0.01; 0.04	0.01; 0.06
Visit 5, n	14	8	9	6

Mean (SD)	0.033 (0.0149)	0.015 (0.0120)	0.026 (0.0159)	0.032 (0.0098)
Median	0.030	0.015	0.020	0.035
Median Range	0.01; 0.06	0.00; 0.03	0.01; 0.06	0.02; 0.04
Visit 6, n	13	8	8	6
Mean (SD)	0.029 (0.0243)	0.026 (0.0169)	0.030 (0.0120)	0.030 (0.0110)
Median	0.020	0.025	0.030	0.030
Median Range	0.01; 0.10	0.00; 0.05	0.01; 0.05	0.01; 0.04
Visit 7, n	13	8	7	6
Mean (SD)	0.032 (0.0276)	0.023 (0.0116)	0.026 (0.0127)	0.027 (0.0250)
Median	0.020	0.020	0.030	0.020
Median Range	0.01; 0.09	0.01; 0.04	0.01; 0.04	0.00; 0.07
Early Withdrawal, n	2	0	0	0
Mean (SD)	0.035 (0.0212)	0	0	0
Median	0.035	0	0	0
Median Range	0.02; 0.05	0	0	0
EOSINOPHILS (GI/L)				
Visit 1 – Pre-dose, n	16	8	8	8
Mean (SD)	0.103 (0.0819)	0.150 (0.1614)	0.058 (0.0477)	0.096 (0.0498)
Median	0.070	0.075	0.060	0.080
Median Range	0.01; 0.25	0.02; 0.51	0.00; 0.14	0.05; 0.20
Visit 1 – 24 hrs post-dose, n	14	7	9	7
Mean (SD)	0.134 (0.1191)	0.130 (0.0744)	0.072 (0.0683)	0.110 (0.0779)
Median	0.125	0.120	0.030	0.100
Median Range	0.00; 0.42	0.03; 0.23	0.00; 0.18	0.00; 0.26
Visit 2, n	13	7	9	8
Mean (SD)	0.159 (0.1135)	0.197 (0.1005)	0.182 (0.1641)	0.148 (0.0918)
Median	0.120	0.220	0.160	0.145
Median Range	0.03; 0.39	0.06; 0.34	0.00; 0.50	0.05; 0.35
Visit 3 – Pre-dose, n	13	8	9	7
Mean (SD)	0.244 (0.3129)	0.264 (0.2057)	0.180 (0.1069)	0.114 (0.0916)
Median	0.120	0.185	0.210	0.080
Median Range	0.06; 1.24	0.10; 0.71	0.03; 0.34	0.00; 0.28
Visit 3 – 3 hrs post-dose, n	12	7	8	7
Mean (SD)	0.143 (0.1323)	0.181 (0.1051)	0.191 (0.1209)	0.161 (0.1024)
Median	0.090	0.140	0.210	0.120
Median Range	0.00; 0.46	0.08; 0.37	0.01; 0.36	0.05; 0.29
Visit 4, n	13	8	8	7
Mean (SD)	0.222 (0.1391)	0.284 (0.2233)	0.166 (0.1481)	0.137 (0.0948)
Median	0.190	0.240	0.125	0.160
Median Range	0.06; 0.47	0.04; 0.62	0.06; 0.52	0.02; 0.27
Visit 5, n	14	8	9	6
Mean (SD)	0.167 (0.0747)	0.283 (0.3284)	0.130 (0.0933)	0.103 (0.0524)
Median	0.155	0.180	0.120	0.105
Median Range	0.05; 0.28	0.07; 1.08	0.01; 0.32	0.04; 0.16
Visit 6, n	13	8	8	6
Mean (SD)	0.181 (0.1087)	0.229 (0.1455)	0.115 (0.0616)	0.145 (0.1205)
Median	0.180	0.205	0.120	0.125
Median Range	0.00; 0.36	0.01; 0.45	0.02; 0.19	0.00; 0.35
Visit 7, n	13	8	7	6
Mean (SD)	0.192 (0.1622)	0.266 (0.2578)	0.237 (0.2050)	0.140 (0.0927)
Median	0.130	0.210	0.190	0.165
Median Range	0.06; 0.66	0.05; 0.83	0.03; 0.68	0.00; 0.25
Early Withdrawal, n	2	0	0	0
Mean (SD)	0.085 (0.0212)	0	0	0

Median	0.085	0	0	0
Median Range	0.07; 0.10	0	0	0
HEMOGLOBIN (G/L)				
Visit 1 – Pre-dose, n	16	8	9	8
Mean (SD)	134.4 (14.58)	136.1 (12.10)	124.4 (10.14)	139.6 (18.62)
Median	132.0	137.0	127.0	143.5
Median Range	106; 160	118; 154	103; 139	100; 159
Visit 1 – 24 hrs post-dose, n	14	7	9	7
Mean (SD)	135.6 (15.61)	118.7 (19.55)	121.8 (11.89)	138.9 (17.68)
Median	135.0	125.0	124.0	144.0
Median Range	101; 165	89; 141	99; 138	106; 162
Visit 2, n	13	7	9	8
Mean (SD)	137.6 (15.69)	135.4 (17.00)	122.4 (8.35)	137.9 (19.69)
Median	144.0	139.0	121.0	143.0
Median Range	110; 158	103; 156	110; 134	98; 158
Visit 3 – Pre-dose, n	13	8	9	7
Mean (SD)	134.5 (13.09)	134.6 (18.39)	127.0 (13.19)	136.0 (17.43)
Median	133.0	139.0	131.0	138.0
Median Range	107; 154	96; 155	101; 143	102; 155
Visit 3 – 3 hrs post-dose, n	12	7	8	7
Mean (SD)	129.6 (15.32)	136.1 (11.01)	121.1 (12.92)	134.9 (14.94)
Median	132.0	139.0	122.0	142.0
Median Range	98; 150	122; 153	100; 143	107; 152
Visit 4, n	13	8	8	7
Mean (SD)	129.8 (18.78)	133.9 (16.37)	127.4 (11.07)	141.1 (18.20)
Median	134.0	132.5	124.5	147.0
Median Range	89; 164	109; 156	117; 145	107; 161
Visit 5, n	14	8	9	7
Mean (SD)	132.8 (11.96)	134.9 (15.23)	128.8 (11.74)	140.0 (27.39)
Median	135.0	136.5	128.0	149.0
Median Range	101; 152	103; 151	108; 146	81; 165
Visit 6, n	14	8	8	6
Mean (SD)	130.5 (14.08)	135.6 (11.70)	129.6 (15.59)	142.7 (13.46)
Median	128.5	135.5	130.0	144.0
Median Range	106; 165	115; 156	108; 149	123; 157
Visit 7, n	13	8	7	6
Mean (SD)	131.7 (17.09)	137.0 (11.14)	129.1 (17.26)	139.8 (13.38)
Median	130.0	134.5	134.0	136.5
Median Range	105; 173	122; 158	110; 155	128; 164
Early Withdrawal, n	2	0	0	0
Mean (SD)	113.0 (36.77)	0	0	0
Median	113.0	0	0	0
Median Range	87; 139	0	0	0
LYMPHOCYTES (GI/L)				
Visit 1 – Pre-dose, n	16	8	8	8
Mean (SD)	2.041 (0.7292)	1.969 (0.4757)	1.441 (0.5652)	1.799 (0.5452)
Median	1.940	1.850	1.375	1.825
Median Range	1.07; 3.28	1.36; 2.81	0.50; 2.12	0.89; 2.64
Visit 1 – 24 hrs post-dose, n	14	7	9	7
Mean (SD)	1.864 (0.6898)	1.589 (0.7617)	1.636 (0.8437)	1.976 (1.0880)
Median	1.730	1.620	1.440	1.430
Median Range	0.92; 3.04	0.74; 2.93	0.40; 3.36	1.02; 3.86
Visit 2, n	13	7	9	8

Mean (SD)	1.842 (0.5998)	1.801 (0.3945)	1.606 (0.9084)	1.836 (0.6851)
Median	1.940	1.910	1.410	1.485
Median Range	0.45; 2.67	1.33; 2.40	0.85; 3.89	1.12; 2.86
Visit 3 – Pre-dose, n	13	8	9	7
Mean (SD)	1.767 (0.5058)	1.986 (0.3675)	1.659 (0.5427)	1.643 (0.7228)
Median	1.740	1.940	1.580	1.470
Median Range	0.90; 2.68	1.42; 2.49	0.77; 2.43	0.91; 2.89
Visit 3 – 3 hrs post-dose, n	12	7	8	7
Mean (SD)	1.880 (0.5627)	2.063 (0.4693)	1.716 (0.5402)	2.047 (1.1691)
Median	1.885	2.230	1.560	1.580
Median Range	1.09; 2.88	1.34; 2.73	1.19; 2.78	1.14; 4.40
Visit 4, n	13	8	8	7
Mean (SD)	2.263 (0.9220)	2.020 (0.7532)	1.639 (0.6544)	2.050 (0.9197)
Median	2.090	1.885	1.505	1.600
Median Range	0.80; 4.22	1.09; 3.44	0.77; 3.00	1.02; 3.40
Visit 5, n	14	8	9	6
Mean (SD)	2.155 (0.7131)	2.181 (0.7200)	1.571 (0.6213)	1.835 (0.9576)
Median	2.065	2.210	1.340	1.480
Median Range	1.01; 3.63	0.97; 3.52	0.74; 2.87	1.13; 3.75
Visit 6, n	13	8	8	6
Mean (SD)	2.060 (0.9464)	2.204 (0.6120)	1.558 (0.5691)	2.243 (1.0075)
Median	1.800	2.210	1.445	1.905
Median Range	0.51; 3.98	1.12; 2.97	0.97; 2.84	1.32; 3.94
Visit 7, n	13	8	7	6
Mean (SD)	2.048 (0.8728)	1.918 (0.4329)	1.550 (0.4638)	1.587 (0.2851)
Median	2.000	1.845	1.660	1.555
Median Range	0.65; 3.67	1.50; 2.85	0.87; 2.21	1.16; 2.00
Early Withdrawal, n	2	0	0	0
Mean (SD)	1.060 (1.0324)	0	0	0
Median	1.060	0	0	0
Median Range	0.33; 1.79	0	0	0
MEAN CORPUSCLE HEMOGLOBIN CONCENTRATION (G/L)				
Visit 1 – Pre-dose, n	16	8	9	8
Mean (SD)	336.6 (10.09)	337.3 (9.00)	334.9 (11.05)	337.1 (3.68)
Median	339.0	336.0	338.0	336.5
Median Range	315; 350	325; 350	308; 345	332; 344
Visit 1 – 24 hrs post-dose, n	14	7	9	7
Mean (SD)	336.7 (8.78)	341.7 (4.64)	335.7 (11.81)	335.4 (4.35)
Median	337.0	340.0	340.0	334.0
Median Range	323; 351	336; 348	306; 346	331; 342
Visit 2, n	13	7	9	8
Mean (SD)	336.4 (11.46)	339.3 (6.73)	335.3 (12.63)	336.1 (2.53)
Median	338.0	341.0	339.0	336.5
Median Range	315; 354	327; 346	309; 347	331; 339
Visit 3 – Pre-dose, n	13	8	9	7
Mean (SD)	335.2 (8.60)	334.9 (8.90)	333.8 (8.57)	333.6 (8.83)
Median	338.0	334.5	339.0	333.0
Median Range	319; 342	325; 348	317; 340	320; 347
Visit 3 – 3 hrs post-dose, n	12	7	8	7
Mean (SD)	336.7 (10.03)	336.0 (5.57)	334.6 (11.53)	334.7 (8.20)
Median	339.0	336.0	336.5	336.0
Median Range	321; 351	328; 346	318; 349	319; 345
Visit 4, n	13	8	8	7
Mean (SD)	335.7 (7.99)	333.8 (11.42)	335.0 (7.43)	336.1 (3.13)

Median	337.0	335.0	335.0	336.0
Median Range	318; 350	310; 348	322; 348	332; 341
Visit 5, n	14	8	9	7
Mean (SD)	333.1 (8.46)	333.8 (8.60)	334.6 (9.66)	330.7 (3.55)
Median	334.5	334.0	335.0	332.0
Median Range	320; 348	322; 349	322; 350	324; 335
Visit 6, n	14	8	8	6
Mean (SD)	331.6 (9.22)	337.8 (7.63)	331.3 (14.79)	335.0 (6.63)
Median	332.5	339.5	338.5	336.0
Median Range	317; 347	327; 347	301; 341	325; 342
Visit 7, n	13	8	7	6
Mean (SD)	335.0 (7.99)	335.8 (6.48)	335.7 (10.70)	338.5 (11.36)
Median	333.0	335.5	335.0	339.5
Median Range	319; 347	325; 346	317; 353	324; 353
Early Withdrawal, n	2	0	0	0
Mean (SD)	334.5 (6.36)	0	0	0
Median	334.5	0	0	0
Median Range	330; 339	0	0	0
MEAN CORPUSCLE HEMOGLOBIN (PG)				
Visit 1 – Pre-dose, n	16	8	9	8
Mean (SD)	31.63 (1.889)	31.24 (1.964)	31.08 (3.471)	32.31 (1.216)
Median	31.90	31.65	31.60	32.70
Median Range	27.6; 34.5	27.3; 33.5	24.7; 37.3	30.2; 33.9
Visit 1 – 24 hrs post-dose, n	14	7	9	7
Mean (SD)	31.34 (1.739)	31.46 (2.235)	31.03 (3.699)	32.30 (1.061)
Median	31.80	31.60	31.60	32.20
Median Range	27.7; 33.9	27.4; 34.6	24.1; 37.7	30.7; 33.8
Visit 2, n	13	7	9	8
Mean (SD)	31.57 (1.884)	31.17 (2.088)	31.03 (3.517)	32.34 (1.095)
Median	32.10	31.50	31.10	32.50
Median Range	27.5; 34.0	27.1; 33.4	24.6; 37.1	30.4; 33.9
Visit 3 – Pre-dose, n	13	8	9	7
Mean (SD)	31.15 (1.853)	31.18 (2.235)	30.83 (3.375)	32.21 (1.318)
Median	31.20	31.55	31.20	32.40
Median Range	27.6; 34.2	26.4; 34.0	24.5; 36.9	29.9; 34.0
Visit 3 – 3 hrs post-dose, n	12	7	8	7
Mean (SD)	30.87 (1.665)	31.16 (2.499)	30.60 (3.789)	32.20 (1.108)
Median	30.95	31.60	30.20	32.40
Median Range	27.4; 33.5	26.4; 34.4	24.6; 36.8	30.2; 33.5
Visit 4, n	13	8	8	7
Mean (SD)	30.80 (1.759)	30.74 (2.389)	31.41 (2.320)	32.26 (0.971)
Median	31.20	31.40	31.25	32.30
Median Range	28.2; 34.1	25.3; 33.3	29.1; 35.6	30.4; 33.4
Visit 5, n	14	8	9	7
Mean (SD)	30.74 (1.591)	30.51 (2.097)	30.76 (3.119)	31.94 (0.864)
Median	31.00	31.10	30.50	32.30
Median Range	28.3; 33.9	25.9; 32.9	25.0; 35.4	30.3; 32.9
Visit 6, n	14	8	8	6
Mean (SD)	30.59 (1.830)	30.60 (2.140)	30.76 (3.078)	31.78 (0.763)
Median	31.25	31.10	30.80	31.45
Median Range	27.4; 33.6	25.8; 32.8	24.4; 34.3	31.3; 33.3
Visit 7, n	13	8	7	6
Mean (SD)	30.61 (1.926)	30.36 (2.072)	31.17 (2.349)	31.35 (0.635)
Median	31.20	31.05	30.90	31.60

Median Range	26.5; 33.8	25.7; 32.6	27.5; 34.0	30.3; 31.9
Early Withdrawal, n	2	0	0	0
Mean (SD)	34.00 (0.424)	0	0	0
Median	34.00	0	0	0
Median Range	33.7; 34.3	0	0	0
MEAN CORPUSCLE VOLUME (FL)				
Visit 1 – Pre-dose, n	16	8	9	8
Mean (SD)	93.9 (4.82)	92.9 (5.54)	92.8 (9.68)	95.8 (4.13)
Median	94.0	93.0	92.0	96.5
Median Range	85; 102	83; 103	80; 113	90; 101
Visit 1 – 24 hrs post-dose, n	14	7	9	7
Mean (SD)	93.1 (5.14)	92.0 (6.27)	92.4 (10.10)	96.3 (2.75)
Median	94.0	93.0	93.0	96.0
Median Range	83; 102	81; 102	79; 113	93; 100
Visit 2, n	13	7	9	8
Mean (SD)	93.9 (5.89)	92.1 (6.36)	92.7 (10.45)	96.3 (3.45)
Median	95.0	92.0	91.0	97.0
Median Range	84; 102	81; 102	80; 116	90; 100
Visit 3 – Pre-dose, n	13	8	9	7
Mean (SD)	93.0 (4.64)	93.0 (6.09)	92.4 (10.43)	96.7 (3.82)
Median	94.0	94.0	92.0	98.0
Median Range	84; 101	81; 103	77; 115	91; 101
Visit 3 – 3 hrs post-dose, n	12	7	8	7
Mean (SD)	91.7 (4.74)	92.7 (6.52)	91.5 (10.35)	96.3 (4.35)
Median	93.0	94.0	89.5	98.0
Median Range	83; 100	81; 103	77; 112	90; 102
Visit 4, n	13	8	8	7
Mean (SD)	91.8 (5.07)	91.8 (5.55)	93.8 (8.29)	96.0 (2.52)
Median	93.0	92.0	91.0	96.0
Median Range	84; 101	81; 101	87; 111	92; 100
Visit 5, n	14	8	9	7
Mean (SD)	92.3 (4.48)	91.5 (5.58)	91.9 (7.99)	96.4 (2.76)
Median	91.5	92.0	92.0	97.0
Median Range	84; 102	80; 99	78; 105	92; 100
Visit 6, n	14	8	8	6
Mean (SD)	92.4 (5.29)	90.5 (6.32)	92.8 (6.61)	95.0 (3.41)
Median	92.5	90.0	92.0	93.5
Median Range	85; 106	78; 99	81; 102	92; 101
Visit 7, n	13	8	7	6
Mean (SD)	91.3 (5.04)	90.4 (5.60)	92.9 (5.70)	92.7 (2.16)
Median	91.0	91.0	91.0	92.5
Median Range	83; 102	79; 98	87; 101	90; 96
Early Withdrawal, n	2	0	0	0
Mean (SD)	101.5 (3.54)	0	0	0
Median	101.5	0	0	0
Median Range	99; 104	0	0	0
MONOCYTES (GI/L)				
Visit 1 – Pre-dose, n	16	8	8	8
Mean (SD)	0.580 (0.2030)	0.429 (0.1001)	0.419 (0.1343)	0.486 (0.2115)
Median	0.575	0.395	0.380	0.530
Median Range	0.26; 1.09	0.29; 0.61	0.32; 0.73	0.23; 0.85
Visit 1 – 24 hrs post-dose, n	14	7	9	7
Mean (SD)	0.529 (0.2077)	0.389 (0.1056)	0.483 (0.1430)	0.497 (0.2326)

Median	0.545	0.400	0.430	0.530
Median Range	0.15; 1.01	0.22; 0.51	0.35; 0.73	0.15; 0.86
Visit 2, n	13	7	9	8
Mean (SD)	0.638 (0.3194)	0.523 (0.2584)	0.400 (0.1568)	0.622 (0.2286)
Median	0.550	0.510	0.400	0.645
Median Range	0.27; 1.48	0.26; 1.03	0.17; 0.69	0.35; 0.95
Visit 3 – Pre-dose, n	13	8	9	7
Mean (SD)	0.636 (0.4465)	0.525 (0.2168)	0.468 (0.1768)	0.357 (0.1009)
Median	0.520	0.490	0.440	0.360
Median Range	0.21; 2.02	0.27; 0.97	0.23; 0.76	0.17; 0.47
Visit 3 – 3 hrs post-dose, n	12	7	8	7
Mean (SD)	0.634 (0.3486)	0.537 (0.2145)	0.573 (0.2200)	0.476 (0.2696)
Median	0.585	0.500	0.535	0.460
Median Range	0.21; 1.61	0.32; 0.95	0.23; 0.92	0.23; 1.03
Visit 4, n	13	8	8	7
Mean (SD)	0.501 (0.1797)	0.394 (0.1609)	0.398 (0.1557)	0.477 (0.2308)
Median	0.490	0.400	0.330	0.390
Median Range	0.27; 0.88	0.20; 0.61	0.24; 0.65	0.26; 0.94
Visit 5, n	14	8	9	6
Mean (SD)	0.496 (0.1840)	0.450 (0.1267)	0.381 (0.1847)	0.495 (0.2254)
Median	0.480	0.440	0.360	0.450
Median Range	0.22; 0.84	0.32; 0.72	0.18; 0.78	0.26; 0.82
Visit 6, n	13	8	8	6
Mean (SD)	0.591 (0.4141)	0.420 (0.1936)	0.448 (0.1038)	0.608 (0.2815)
Median	0.480	0.470	0.425	0.560
Median Range	0.16; 1.70	0.17; 0.66	0.31; 0.63	0.32; 1.03
Visit 7, n	13	8	7	6
Mean (SD)	0.505 (0.1941)	0.433 (0.1547)	0.357 (0.0616)	0.475 (0.2381)
Median	0.480	0.435	0.370	0.430
Median Range	0.29; 0.98	0.16; 0.66	0.29; 0.45	0.13; 0.85
Early Withdrawal, n	2	0	0	0
Mean (SD)	0.370 (0.2687)	0	0	0
Median	0.370	0	0	0
Median Range	0.18; 0.56	0	0	0
TOTAL NEUTROPHILS (TOTAL ANC – TOTAL ABSOLUTE NEUTROPHIL COUNT) (G/L)				
Visit 1 – Pre-dose, n	16	8	8	8
Mean (SD)	5.779 (1.7059)	5.306 (1.9088)	6.538 (1.1240)	6.694 (1.4189)
Median	5.855	5.355	6.520	6.530
Median Range	1.84; 9.23	1.55; 7.91	4.43; 8.33	4.83; 8.55
Visit 1 – 24 hrs post-dose, n	14	7	9	7
Mean (SD)	5.813 (2.1571)	5.739 (2.2411)	5.868 (1.5120)	6.031 (0.7494)
Median	5.270	5.730	5.390	6.230
Median Range	3.29; 11.51	3.88; 10.44	4.01; 8.56	5.06; 7.18
Visit 2, n	13	7	9	8
Mean (SD)	5.118 (2.4497)	4.573 (1.4927)	6.426 (3.3211)	6.821 (2.8407)
Median	4.300	5.170	5.550	5.385
Median Range	2.82; 11.96	2.30; 6.13	3.58; 14.87	4.76; 12.35
Visit 3 – Pre-dose, n	13	8	9	7
Mean (SD)	5.635 (2.8342)	6.073 (1.5238)	5.539 (1.7778)	5.057 (1.6991)
Median	5.000	5.540	4.980	5.170
Median Range	2.85; 11.73	4.39; 7.95	3.42; 8.63	2.40; 7.41
Visit 3 – 3 hrs post-dose, n	12	7	8	7
Mean (SD)	5.733 (3.3572)	5.794 (1.6360)	5.333 (1.9108)	5.084 (2.1641)
Median	4.925	5.340	4.915	4.530

Median Range	2.74; 14.46	3.99; 8.39	3.49; 9.22	2.52; 7.72
Visit 4, n	13	8	8	7
Mean (SD)	4.656 (1.8481)	5.141 (1.7027)	4.413 (0.8033)	5.056 (1.7894)
Median	4.870	4.790	4.400	5.030
Median Range	2.00; 8.44	2.97; 8.17	3.50; 6.16	2.13; 6.91
Visit 5, n	14	8	9	6
Mean (SD)	5.100 (2.8561)	6.050 (1.3212)	4.840 (1.5553)	5.568 (2.2724)
Median	4.670	6.150	4.430	5.740
Median Range	0.16; 13.17	3.48; 7.45	3.19; 7.83	1.57; 7.97
Visit 6, n	13	8	8	6
Mean (SD)	4.892 (2.8926)	5.110 (1.9405)	5.679 (1.4786)	5.037 (1.8762)
Median	4.090	4.680	5.245	5.015
Median Range	1.27; 13.40	2.62; 8.25	4.32; 8.60	1.80; 7.33
Visit 7, n	13	8	7	6
Mean (SD)	5.072 (1.9203)	5.750 (3.6621)	4.203 (0.7083)	4.690 (1.8738)
Median	4.860	4.585	4.170	4.705
Median Range	2.88; 10.20	2.78; 13.83	3.04; 5.40	2.01; 7.15
Early Withdrawal, n	2	0	0	0
Mean (SD)	3.705 (1.2657)	0	0	0
Median	3.705	0	0	0
Median Range	2.81; 4.60	0	0	0
PLATELET COUNT (GI/L)				
Visit 1 – Pre-dose, n	16	8	9	8
Mean (SD)	213.4 (80.44)	187.9 (45.21)	207.7 (46.85)	247.3 (46.23)
Median	180.5	192.0	181.0	227.0
Median Range	120; 366	113; 266	172; 302	197; 311
Visit 1 – 24 hrs post-dose, n	14	7	9	7
Mean (SD)	220.6 (81.15)	171.6 (52.07)	207.2 (55.51)	255.1 (46.86)
Median	204.0	160.0	190.0	275.0
Median Range	129; 379	108; 269	154; 310	177; 298
Visit 2, n	13	7	9	8
Mean (SD)	251.2 (78.86)	211.9 (36.35)	220.6 (66.37)	259.6 (85.57)
Median	232.0	199.0	192.0	231.0
Median Range	156; 385	180; 290	152; 361	170; 365
Visit 3 – Pre-dose, n	12	8	9	7
Mean (SD)	293.6 (76.57)	256.4 (59.58)	283.0 (82.66)	253.3 (92.26)
Median	277.5	255.0	248.0	209.0
Median Range	217; 476	177; 354	189; 386	160; 377
Visit 3 – 3 hrs post-dose, n	12	7	8	7
Mean (SD)	293.3 (73.66)	259.3 (50.17)	293.6 (82.05)	266.7 (93.13)
Median	284.0	247.0	298.0	205.0
Median Range	215; 467	189; 334	197; 414	176; 376
Visit 4, n	13	8	8	7
Mean (SD)	304.8 (171.42)	243.9 (72.24)	241.1 (75.25)	258.9 (71.73)
Median	230.0	229.5	222.5	261.0
Median Range	148; 743	155; 404	181; 413	176; 341
Visit 5, n	13	8	8	7
Mean (SD)	300.9 (147.76)	259.4 (72.95)	265.6 (61.39)	235.0 (64.62)
Median	240.0	255.0	250.5	224.0
Median Range	143; 661	164; 395	195; 371	156; 308
Visit 6, n	14	7	8	6
Mean (SD)	270.4 (108.19)	231.9 (60.13)	275.0 (99.82)	241.8 (64.32)
Median	226.5	223.0	241.0	218.0
Median Range	157; 488	128; 328	197; 460	175; 326

Visit 7, n	13	8	7	6
Mean (SD)	275.8 (103.66)	237.1 (73.13)	242.3 (52.22)	270.3 (91.04)
Median	241.0	240.5	239.0	282.5
Median Range	157; 489	106; 360	197; 354	157; 362
Early Withdrawal, n	2	0	0	0
Mean (SD)	174.5 (4.95)	0	0	0
Median	174.5	0	0	0
Median Range	171; 178	0	0	0
RED BLOOD CELL COUNT (TI/L)				
Visit 1 – Pre-dose, n	16	8	9	8
Mean (SD)	4.26 (0.519)	4.39 (0.488)	4.03 (0.320)	4.31 (0.525)
Median	4.15	4.35	4.10	4.50
Median Range	3.5; 5.5	3.8; 5.1	3.4; 4.4	3.2; 4.7
Visit 1 – 24 hrs post-dose, n	14	7	9	7
Mean (SD)	4.34 (0.536)	3.80 (0.810)	3.94 (0.240)	4.31 (0.515)
Median	4.30	3.60	3.90	4.30
Median Range	3.2; 5.4	2.9; 5.2	3.6; 4.3	3.4; 5.0
Visit 2, n	13	7	9	8
Mean (SD)	4.37 (0.563)	4.36 (0.660)	3.98 (0.319)	4.28 (0.625)
Median	4.30	4.40	3.90	4.30
Median Range	3.4; 5.4	3.4; 5.3	3.5; 4.5	3.1; 5.0
Visit 3 – Pre-dose, n	13	8	9	7
Mean (SD)	4.34 (0.482)	4.36 (0.735)	4.13 (0.304)	4.23 (0.556)
Median	4.30	4.30	4.20	4.30
Median Range	3.5; 5.3	3.0; 5.5	3.6; 4.5	3.2; 4.8
Visit 3 – 3 hrs post-dose, n	12	7	8	7
Mean (SD)	4.19 (0.530)	4.40 (0.523)	3.99 (0.264)	4.17 (0.512)
Median	4.20	4.20	4.10	4.30
Median Range	3.2; 5.3	3.8; 5.3	3.4; 4.2	3.3; 4.7
Visit 4, n	13	8	8	7
Mean (SD)	4.21 (0.559)	4.39 (0.649)	4.06 (0.292)	4.40 (0.622)
Median	4.30	4.25	4.00	4.60
Median Range	3.2; 5.1	3.5; 5.3	3.5; 4.5	3.3; 5.0
Visit 5, n	14	8	9	7
Mean (SD)	4.33 (0.375)	4.44 (0.639)	4.20 (0.343)	4.37 (0.864)
Median	4.30	4.35	4.30	4.60
Median Range	3.5; 5.0	3.3; 5.4	3.6; 4.7	2.5; 5.1
Visit 6, n	14	8	8	6
Mean (SD)	4.28 (0.430)	4.48 (0.537)	4.24 (0.510)	4.48 (0.397)
Median	4.20	4.40	4.35	4.55
Median Range	3.7; 5.2	3.8; 5.5	3.4; 4.8	3.9; 5.0
Visit 7, n	13	8	7	6
Mean (SD)	4.31 (0.524)	4.55 (0.555)	4.16 (0.526)	4.45 (0.432)
Median	4.10	4.45	4.20	4.30
Median Range	3.7; 5.4	4.0; 5.6	3.3; 5.0	4.0; 5.2
Early Withdrawal, n	2	0	0	0
Mean (SD)	3.30 (1.131)	0	0	0
Median	3.30	0	0	0
Median Range	2.5; 4.1	0	0	0
RETICULOCYTES (TI/L)				
Visit 1 – Pre-dose, n	3	4	0	0
Mean (SD)	0.06703 (0.014672)	0.04135 (0.014310)	0	0

Median	0.06300	0.04345	0	0
Median Range	0.0548; 0.0833	0.0221; 0.0564	0	0
Visit 1 – 24 hrs post-dose, n	3	3	0	0
Mean (SD)	0.06213 (0.029508)	0.04617 (0.036532)	0	0
Median	0.04920	0.03280	0	0
Median Range	0.0413; 0.0959	0.0182; 0.0875	0	0
Visit 2, n	6	4	0	0
Mean (SD)	0.08522 (0.033462)	0.04638 (0.009777)	0	0
Median	0.09085	0.04605	0	0
Median Range	0.0379; 0.1288	0.0348; 0.0586	0	0
Visit 3 – Pre-dose, n	13	8	9	7
Mean (SD)	0.06142 (0.019113)	0.07001 (0.034052)	0.07541 (0.026420)	0.05267 (0.018528)
Median	0.06140	0.06905	0.06300	0.05010
Median Range	0.0330; 0.0967	0.0355; 0.1092	0.0481; 0.1280	0.0366; 0.0914
Visit 3 – 3 hrs post-dose, n	12	7	8	7
Mean (SD)	0.05468 (0.020930)	0.06067 (0.025415)	0.07281 (0.023953)	0.05499 (0.023090)
Median	0.05625	0.04860	0.06580	0.05170
Median Range	0.0266; 0.0951	0.0353; 0.0959	0.0461; 0.1119	0.0349; 0.1018
Visit 4, n	13	8	8	7
Mean (SD)	0.05042 (0.027798)	0.05338 (0.027219)	0.06210 (0.028370)	0.06961 (0.034369)
Median	0.04150	0.05420	0.05640	0.06910
Median Range	0.0171; 0.1007	0.0216; 0.0890	0.0376; 0.1280	0.0197; 0.1338
Visit 5, n	14	8	9	7
Mean (SD)	0.05943 (0.021755)	0.06061 (0.026445)	0.06337 (0.029592)	0.05571 (0.016508)
Median	0.05435	0.06435	0.05920	0.06450
Median Range	0.0230; 0.1004	0.0244; 0.0892	0.0229; 0.1171	0.0286; 0.0756
Visit 6, n	14	8	8	6
Mean (SD)	0.04759 (0.010516)	0.04705 (0.016016)	0.05581 (0.016268)	0.07028 (0.024718)
Median	0.05340	0.05040	0.06050	0.07705
Median Range	0.0243; 0.0608	0.0231; 0.0642	0.0344; 0.0776	0.0280; 0.0959
Visit 7, n	13	8	7	6
Mean (SD)	0.05414 (0.016983)	0.05598 (0.019689)	0.04886 (0.013160)	0.06220 (0.012936)
Median	0.05150	0.05630	0.05600	0.05715
Median Range	0.0274; 0.0779	0.0263; 0.0777	0.0296; 0.0617	0.0526; 0.0868
Early Withdrawal, n	2	0	0	0
Mean (SD)	0.10785 (0.083792)	0	0	0
Median	0.10785	0	0	0
Median Range	0.0486; 0.1671	0	0	0
WHITE BLOOD CELL COUNT (GI/L)				
Visit 1 – Pre-dose, n	16	8	8	8
Mean (SD)	8.54 (1.523)	7.88 (2.014)	8.48 (0.945)	9.10 (1.834)
Median	8.40	8.10	8.45	9.30
Median Range	5.9; 10.9	3.6; 10.3	6.8; 10.1	6.6; 11.1
Visit 1 – 24 hrs post-dose, n	14	7	9	7
Mean (SD)	8.37 (2.266)	7.86 (2.174)	8.08 (1.406)	8.64 (1.388)

Median	7.75	7.30	8.00	8.70
Median Range	5.9; 13.1	5.2; 12.1	5.5; 10.5	7.0 10.1
Visit 2, n	13	7	9	8
Mean (SD)	7.78 (3.133)	7.13 (1.586)	8.62 (3.347)	9.45 (2.994)
Median	7.60	7.40	7.80	8.95
Median Range	3.6; 16.3	4.8; 9.3	5.1; 16.5	6.3; 14.7
Visit 3 – Pre-dose, n	13	8	9	7
Mean (SD)	8.31 (3.136)	8.89 (1.745)	7.87 (2.219)	7.20 (2.412)
Median	7.20	8.05	7.10	7.70
Median Range	4.6; 15.5	7.3; 11.7	5.0; 11.3	3.8; 11.0
Visit 3 – 3 hrs post-dose, n	12	7	8	7
Mean (SD)	8.43 (3.414)	8.61 (2.147)	7.84 (2.436)	7.79 (2.963)
Median	7.90	7.30	7.30	8.40
Median Range	5.0; 17.3	6.3; 12.0	5.3; 12.0	4.3; 12.6
Visit 4, n	13	8	8	7
Mean (SD)	7.68 (2.591)	7.86 (1.647)	6.64 (1.439)	7.74 (2.402)
Median	7.10	8.25	6.25	7.80
Median Range	4.0; 13.7	5.2; 10.2	5.5; 10.0	3.8; 11.2
Visit 5, n	14	8	9	6
Mean (SD)	7.95 (3.431)	8.98 (0.833)	6.94 (2.191)	8.03 (2.796)
Median	6.90	8.90	6.10	8.35
Median Range	2.9; 17.8	7.9; 10.2	4.9; 10.8	3.1; 10.8
Visit 6, n	13	8	8	6
Mean (SD)	7.75 (4.023)	7.99 (2.342)	7.83 (1.693)	8.07 (2.595)
Median	6.80	8.10	7.15	8.35
Median Range	3.9; 19.5	5.1; 11.8	5.8; 10.4	3.5; 11.2
Visit 7, n	13	8	7	6
Mean (SD)	7.85 (2.760)	8.39 (3.601)	6.37 (0.907)	6.92 (2.179)
Median	6.70	7.15	6.40	7.60
Median Range	5.6; 15.6	5.3; 16.5	5.2; 7.8	3.3; 9.2
Early Withdrawal, n	2	0	0	0
Mean (SD)	5.25 (0.071)	0	0	0
Median	5.25	0	0	0
Median Range	5.2; 5.3	0	0	0
Summary of Chemistry Lab Values (Reference ranges available upon request)				
Treatment Group	Placebo N=17	GSK249320 1 mg/kg N=8	GSK249320 5 mg/kg N=9	GSK249320 15 mg/kg N=8
ALBUMIN (G/L)				
Visit 1 – Pre-dose, n	16	8	9	8
Mean (SD)	38.9 (5.69)	39.0 (4.24)	37.2 (4.18)	38.9 (6.47)
Median	39.5	37.5	37.0	39.0
Median Range	25; 46	34; 46	29; 44	24; 45
Visit 1 – 24 hrs post-dose, n	15	7	7	7
Mean (SD)	38.3 (4.92)	34.7 (4.82)	36.3 (4.89)	39.3 (4.46)
Median	38.0	36.0	35.0	39.0
Median Range	30; 45	29; 42	30; 44	32; 47
Visit 2, n	14	7	9	8
Mean (SD)	40.8 (5.38)	39.6 (4.93)	38.0 (6.52)	39.9 (6.73)
Median	42.0	42.0	38.0	41.0
Median Range	31; 50	30; 45	29; 50	26; 46
Visit 3 – Pre-dose, n	13	8	8	7
Mean (SD)	40.0 (4.88)	41.0 (4.11)	40.1 (6.08)	38.6 (7.46)

Median	40.0	42.5	41.0	42.0
Median Range	32; 48	32; 44	31; 47	25; 45
Visit 3 – 3 hrs post-dose, n	14	7	8	7
Mean (SD)	39.0 (4.80)	40.9 (2.34)	39.5 (5.48)	38.0 (6.78)
Median	37.0	41.0	39.0	41.0
Median Range	33; 46	38; 44	33; 46	26; 44
Visit 4, n	13	8	8	6
Mean (SD)	41.5 (4.24)	43.3 (4.65)	41.4 (2.77)	43.0 (7.43)
Median	42.0	43.0	40.5	45.5
Median Range	33; 48	36; 50	39; 46	30; 50
Visit 5, n	14	8	9	6
Mean (SD)	44.1 (3.06)	42.9 (4.36)	42.8 (4.41)	42.7 (9.95)
Median	45.0	43.0	43.0	45.5
Median Range	39; 49	34; 48	35; 50	25; 52
Visit 6, n	14	7	8	6
Mean (SD)	43.5 (2.88)	44.0 (4.76)	43.9 (4.58)	45.2 (2.79)
Median	43.5	44.0	45.0	44.5
Median Range	39; 49	35; 50	37; 51	42; 49
Visit 7, n	14	8	8	6
Mean (SD)	43.3 (3.10)	43.4 (4.07)	45.5 (4.72)	44.3 (3.39)
Median	44.0	44.0	45.0	44.0
Median Range	39; 48	35; 48	38; 54	41; 50
Early Withdrawal, n	2	0	0	0
Mean (SD)	35.0 (9.90)	0	0	0
Median	35.0	0	0	0
Median Range	28; 42	0	0	0
ALKALINE PHOSPHATASE (IU/L)				
Visit 1 – Pre-dose, n	16	8	9	8
Mean (SD)	74.8 (37.12)	72.5 (22.96)	61.3 (12.53)	74.8 (15.55)
Median	66.0	84.0	60.0	73.0
Median Range	25; 187	37; 95	46; 79	50; 96
Visit 1 – 24 hrs post-dose, n	15	7	7	6
Mean (SD)	72.1 (36.85)	61.7 (22.00)	56.9 (12.64)	72.7 (13.94)
Median	61.0	59.0	61.0	73.0
Median Range	27; 179	33; 86	41; 72	53; 89
Visit 2, n	14	7	9	8
Mean (SD)	78.7 (40.55)	70.4 (25.24)	61.1 (11.29)	71.9 (16.70)
Median	71.0	84.0	63.0	68.0
Median Range	26; 180	38; 96	48; 81	52; 100
Visit 3 – Pre-dose, n	13	8	8	6
Mean (SD)	80.4 (40.63)	78.3 (24.12)	65.1 (14.00)	71.5 (19.28)
Median	68.0	83.5	62.0	72.5
Median Range	30; 184	47; 108	41; 85	45; 91
Visit 3 – 3 hrs post-dose, n	13	7	8	7
Mean (SD)	78.9 (42.24)	76.6 (26.30)	64.4 (14.99)	71.1 (18.24)
Median	68.0	90.0	63.5	62.0
Median Range	30; 187	46; 112	43; 88	48; 92
Visit 4, n	13	8	8	6
Mean (SD)	86.0 (46.28)	78.3 (24.61)	67.8 (16.46)	72.0 (20.52)
Median	76.0	80.5	67.0	71.5
Median Range	32; 202	36; 114	47; 96	48; 96
Visit 5, n	14	8	9	6
Mean (SD)	83.1 (48.53)	84.6 (31.65)	66.0 (13.80)	93.0 (25.61)
Median	66.0	82.0	66.0	90.0

Median Range	26; 206	43; 134	39; 86	55; 129
Visit 6, n	14	7	8	6
Mean (SD)	79.3 (50.36)	93.3 (39.98)	71.6 (18.17)	93.7 (25.07)
Median	63.5	87.0	68.0	95.5
Median Range	27; 234	42; 147	51; 108	51; 129
Visit 7, n	14	8	8	6
Mean (SD)	75.5 (43.47)	78.8 (22.67)	74.5 (12.97)	83.3 (23.62)
Median	66.0	81.5	74.5	83.0
Median Range	30; 209	44; 120	54; 93	54; 121
Early Withdrawal, n	2	0	0	0
Mean (SD)	103.0 (35.36)	0	0	0
Median	103.0	0	0	0
Median Range	78; 128	0	0	0
ALANINE AMINOTRANSFERASE (IU/L)				
Visit 1 – Pre-dose, n	16	8	9	8
Mean (SD)	22.7 (16.10)	17.6 (5.01)	13.3 (7.70)	20.6 (11.54)
Median	19.0	19.5	10.0	17.0
Median Range	9; 74	9; 23	7; 29	12; 48
Visit 1 – 24 hrs post-dose, n	15	7	7	7
Mean (SD)	24.3 (17.39)	14.9 (4.22)	15.9 (15.43)	21.3 (13.38)
Median	21.0	15.0	9.0	16.0
Median Range	10; 72	8; 19	6; 49	14; 51
Visit 2, n	14	7	9	8
Mean (SD)	26.8 (10.24)	30.3 (13.79)	23.7 (23.12)	22.9 (11.32)
Median	27.0	24.0	12.0	19.5
Median Range	11; 48	18; 58	10; 70	12; 41
Visit 3 – Pre-dose, n	13	8	8	7
Mean (SD)	33.5 (22.97)	32.9 (15.70)	34.4 (25.39)	25.1 (10.82)
Median	24.0	26.5	28.0	25.0
Median Range	12; 79	20; 62	10; 90	13; 45
Visit 3 – 3 hrs post-dose, n	14	7	8	7
Mean (SD)	30.9 (22.22)	32.7 (15.21)	34.1 (26.35)	24.6 (11.13)
Median	19.5	28.0	27.5	23.0
Median Range	13; 75	19; 56	10; 93	13; 46
Visit 4, n	13	8	8	6
Mean (SD)	26.3 (11.94)	29.8 (14.32)	28.1 (33.77)	25.2 (9.02)
Median	24.0	26.0	14.5	22.0
Median Range	9; 55	9; 49	8; 109	17; 41
Visit 5, n	14	8	9	6
Mean (SD)	21.8 (10.47)	32.1 (26.81)	14.1 (8.42)	35.8 (24.85)
Median	19.0	23.5	11.0	29.5
Median Range	9; 42	7; 84	7; 34	10; 74
Visit 6, n	14	7	8	6
Mean (SD)	24.1 (12.06)	32.7 (23.03)	14.4 (5.48)	38.7 (43.72)
Median	19.5	22.0	13.0	22.0
Median Range	12; 50	10; 65	8; 24	8; 126
Visit 7, n	14	8	8	6
Mean (SD)	17.6 (7.79)	26.6 (21.02)	14.4 (4.44)	66.5 (90.75)
Median	16.5	21.5	15.0	38.0
Median Range	9; 41	9; 71	8; 20	12; 250
Early Withdrawal, n	2	0	0	0
Mean (SD)	36.5 (10.61)	0	0	0
Median	36.5	0	0	0
Median Range	29; 44	0	0	0

ASPARTATE AMINOTRANSFERASE (IU/L)				
Visit 1 – Pre-dose, n	16	8	9	8
Mean (SD)	24.6 (8.60)	19.4 (6.25)	19.7 (8.25)	22.6 (8.21)
Median	21.5	18.5	17.0	23.0
Median Range	14; 46	12; 33	12; 33	12; 37
Visit 1 – 24 hrs post-dose, n	15	7	7	7
Mean (SD)	27.7 (12.03)	17.4 (6.21)	23.6 (16.58)	22.1 (6.59)
Median	24.0	18.0	18.0	22.0
Median Range	13; 55	8; 26	12; 60	15; 35
Visit 2, n	14	7	9	8
Mean (SD)	32.2 (12.24)	30.7 (13.66)	29.1 (20.98)	23.9 (9.46)
Median	31.5	28.0	20.0	22.0
Median Range	13; 62	21; 61	15; 74	14; 36
Visit 3 – Pre-dose, n	13	8	8	7
Mean (SD)	30.2 (16.61)	24.5 (6.97)	32.4 (14.98)	29.7 (11.41)
Median	26.0	22.5	31.0	33.0
Median Range	13; 72	17; 37	14; 65	16; 43
Visit 3 – 3 hrs post-dose, n	13	7	8	7
Mean (SD)	25.6 (8.65)	24.1 (6.49)	28.5 (12.46)	29.6 (8.12)
Median	24.0	23.0	26.0	34.0
Median Range	16; 45	18; 38	13; 56	17; 39
Visit 4, n	13	8	8	6
Mean (SD)	29.7 (18.56)	21.6 (4.93)	36.8 (47.82)	26.3 (9.46)
Median	24.0	22.5	17.5	25.0
Median Range	12; 86	14; 29	12; 152	15; 42
Visit 5, n	14	8	9	6
Mean (SD)	22.3 (9.07)	26.5 (15.46)	18.4 (3.81)	45.0 (38.40)
Median	20.0	20.0	18.0	27.0
Median Range	13; 50	15; 62	15; 27	12; 103
Visit 6, n	14	7	8	5
Mean (SD)	23.6 (15.11)	26.9 (11.51)	16.3 (4.13)	41.0 (46.87)
Median	19.0	24.0	15.0	18.0
Median Range	14; 74	16; 47	13; 25	12; 123
Visit 7, n	14	8	8	5
Mean (SD)	20.5 (7.07)	19.4 (5.71)	19.3 (4.43)	64.4 (77.96)
Median	18.5	18.0	18.0	41.0
Median Range	12; 37	12; 28	14; 26	12; 201
Early Withdrawal, n	2	0	0	0
Mean (SD)	33.0 (7.07)	0	0	0
Median	33.0	0	0	0
Median Range	28; 38	0	0	0
BILIRUBIN, DIRECT (UMOL/L)				
Visit 1 – Pre-dose, n	16	8	9	8
Mean (SD)	2.9 (1.44)	2.0 (0.53)	1.7 (1.12)	3.6 (2.83)
Median	2.5	2.0	2.0	3.0
Median Range	1; 6	1; 3	0; 4	1; 10
Visit 1 – 24 hrs post-dose, n	15	7	7	7
Mean (SD)	3.1 (1.83)	1.7 (0.95)	2.1 (1.77)	2.9 (2.48)
Median	2.0	2.0	2.0	2.0
Median Range	1; 6	0; 3	1; 6	1; 8
Visit 2, n	14	7	9	8
Mean (SD)	3.1 (1.83)	1.9 (0.69)	1.8 (0.97)	2.4 (1.51)
Median	3.0	2.0	2.0	2.0

Median Range	1; 8	1; 3	1; 4	1; 6
Visit 3 – Pre-dose, n	13	8	8	7
Mean (SD)	2.2 (0.93)	2.1 (0.64)	1.6 (0.92)	1.9 (1.07)
Median	2.0	2.0	2.0	2.0
Median Range	1; 4	1; 3	0; 3	1; 4
Visit 3 – 3 hrs post-dose, n	14	7	8	7
Mean (SD)	2.0 (1.36)	1.6 (0.98)	1.5 (0.76)	1.7 (1.11)
Median	2.0	2.0	2.0	1.0
Median Range	0; 5	0; 3	0; 2	1; 4
Visit 4, n	13	8	8	6
Mean (SD)	2.1 (1.12)	2.3 (0.89)	2.1 (1.25)	2.2 (0.98)
Median	2.0	2.0	2.0	2.0
Median Range	0; 4	1; 4	1; 4	1; 4
Visit 5, n	14	8	9	6
Mean (SD)	1.8 (0.97)	1.9 (0.64)	1.8 (0.97)	2.2 (0.41)
Median	1.5	2.0	2.0	2.0
Median Range	1; 4	1; 3	1; 4	2; 3
Visit 6, n	14	7	8	6
Mean (SD)	1.9 (1.33)	1.7 (1.11)	2.0 (0.93)	2.7 (1.03)
Median	2.0	2.0	2.0	2.0
Median Range	1; 6	0; 3	1; 4	2; 4
Visit 7, n	14	8	8	6
Mean (SD)	2.0 (1.36)	2.0 (0.76)	1.5 (0.76)	2.2 (1.47)
Median	2.0	2.0	1.0	1.5
Median Range	0; 5	1; 3	1; 3	1; 4
Early Withdrawal, n	2	0	0	0
Mean (SD)	3.5 (0.71)	0	0	0
Median	3.5	0	0	0
Median Range	3; 4	0	0	0
BILIRUBIN, TOTAL (UMOL/L)				
Visit 1 – Pre-dose, n	16	8	9	8
Mean (SD)	14.1 (5.86)	10.5 (6.63)	9.3 (2.55)	14.8 (7.03)
Median	12.5	9.0	8.0	13.5
Median Range	5; 25	4; 25	5; 13	6; 30
Visit 1 – 24 hrs post-dose, n	15	7	7	7
Mean (SD)	12.8 (5.02)	8.1 (2.04)	9.9 (4.30)	11.6 (5.53)
Median	13.0	8.0	9.0	10.0
Median Range	4; 19	6; 12	6; 18	8; 24
Visit 2, n	14	7	9	8
Mean (SD)	13.5 (6.20)	8.6 (3.15)	8.6 (4.59)	10.8 (3.99)
Median	13.5	7.0	8.0	10.0
Median Range	6; 28	6; 14	4; 20	4; 16
Visit 3 – Pre-dose, n	13	8	8	6
Mean (SD)	9.1 (2.02)	9.0 (3.66)	7.1 (2.42)	6.2 (2.04)
Median	9.0	8.0	6.5	6.0
Median Range	6; 14	6; 16	4; 11	4; 10
Visit 3 – 3 hrs post-dose, n	14	7	8	7
Mean (SD)	7.6 (2.47)	8.6 (3.41)	7.0 (1.85)	6.4 (2.57)
Median	7.5	7.0	6.5	6.0
Median Range	3; 13	5; 13	5; 11	2; 10
Visit 4, n	13	8	8	6
Mean (SD)	9.0 (3.81)	9.6 (5.45)	9.0 (4.14)	8.7 (2.94)
Median	9.0	8.0	8.0	7.5
Median Range	4; 18	6; 22	6; 19	6; 14

Visit 5, n	14	8	9	6
Mean (SD)	9.1 (3.56)	9.1 (5.03)	8.8 (3.70)	10.0 (3.85)
Median	8.0	7.5	8.0	9.0
Median Range	5; 16	4; 20	5; 18	6; 17
Visit 6, n	14	7	8	6
Mean (SD)	8.9 (3.93)	8.9 (4.71)	8.3 (1.83)	11.8 (6.21)
Median	8.0	6.0	8.5	10.0
Median Range	5; 19	4; 17	6; 11	7; 24
Visit 7, n	14	8	8	6
Mean (SD)	8.9 (4.25)	8.5 (4.90)	8.4 (3.34)	8.5 (2.95)
Median	7.0	7.5	7.0	8.0
Median Range	5; 18	4; 20	6; 16	5; 12
Early Withdrawal, n	2	0	0	0
Mean (SD)	13.5 (0.71)	0	0	0
Median	13.5	0	0	0
Median Range	13; 14	0	0	0
CALCIUM (MMOL/L)				
Visit 1 – Pre-dose, n	15	8	9	8
Mean (SD)	2.196 (0.2323)	2.156 (0.1184)	2.193 (0.1564)	2.231 (0.1772)
Median	2.270	2.140	2.220	2.235
Median Range	1.68; 2.44	2.02; 2.32	1.84; 2.41	1.92; 2.49
Visit 1 – 24 hrs post-dose, n	15	7	7	6
Mean (SD)	2.221 (0.1542)	2.067 (0.1463)	2.136 (0.1609)	2.267 (0.1451)
Median	2.250	2.100	2.110	2.200
Median Range	1.88; 2.44	1.90; 2.27	1.90; 2.39	2.16; 2.54
Visit 2, n	14	7	9	8
Mean (SD)	2.299 (0.1153)	2.233 (0.1385)	2.250 (0.1545)	2.286 (0.1303)
Median	2.315	2.200	2.160	2.275
Median Range	2.03; 2.43	2.05; 2.45	2.04; 2.45	2.08; 2.52
Visit 3 – Pre-dose, n	13	8	8	6
Mean (SD)	2.331 (0.1235)	2.323 (0.0734)	2.331 (0.1675)	2.242 (0.1477)
Median	2.280	2.335	2.380	2.315
Median Range	2.20; 2.60	2.20; 2.42	2.10; 2.55	2.02; 2.37
Visit 3 – 3 hrs post-dose, n	14	7	8	7
Mean (SD)	2.266 (0.0866)	2.310 (0.0658)	2.288 (0.1369)	2.220 (0.1518)
Median	2.280	2.310	2.270	2.300
Median Range	2.12; 2.40	2.24; 2.42	2.13; 2.53	1.97; 2.34
Visit 4, n	13	8	8	6
Mean (SD)	2.378 (0.0832)	2.365 (0.1344)	2.364 (0.0776)	2.357 (0.1450)
Median	2.360	2.400	2.370	2.390
Median Range	2.21; 2.51	2.10; 2.53	2.26; 2.50	2.12; 2.52
Visit 5, n	14	8	9	6
Mean (SD)	2.402 (0.0903)	2.343 (0.1467)	2.348 (0.1155)	2.387 (0.1826)
Median	2.420	2.405	2.350	2.425
Median Range	2.24; 2.57	2.09; 2.48	2.22; 2.58	2.04; 2.56
Visit 6, n	14	7	8	5
Mean (SD)	2.396 (0.0727)	2.379 (0.0867)	2.378 (0.1479)	2.454 (0.1048)
Median	2.430	2.400	2.355	2.470
Median Range	2.27; 2.50	2.20; 2.47	2.11; 2.55	2.28; 2.56
Visit 7, n	14	8	8	6
Mean (SD)	2.371 (0.0776)	2.386 (0.0785)	2.450 (0.1252)	2.425 (0.1050)
Median	2.345	2.410	2.480	2.420
Median Range	2.26; 2.49	2.22; 2.47	2.24; 2.63	2.29; 2.54
Early Withdrawal, n	2	0	0	0

Mean (SD)	2.140 (0.0849)	0	0	0
Median	2.140	0	0	0
Median Range	2.08; 2.20	0	0	0
CHLORIDE (MMOL/L)				
Visit 1 – Pre-dose, n	15	8	9	8
Mean (SD)	104.6 (4.37)	106.8 (2.66)	107.1 (4.57)	104.8 (3.24)
Median	103.0	107.0	107.0	105.5
Median Range	100; 114	103; 110	101; 117	99; 109
Visit 1 – 24 hrs post-dose, n	15	7	7	7
Mean (SD)	105.9 (4.59)	107.7 (1.60)	106.4 (5.88)	105.1 (3.39)
Median	105.0	107.0	105.0	105.0
Median Range	101; 119	106; 110	102; 118	102; 112
Visit 2, n	14	7	9	8
Mean (SD)	103.1 (4.23)	106.3 (2.63)	104.8 (3.19)	105.1 (3.94)
Median	102.5	106.0	105.0	105.0
Median Range	95; 112	103; 111	101; 109	100; 113
Visit 3 – Pre-dose, n	13	8	8	7
Mean (SD)	103.5 (4.25)	104.0 (2.83)	103.3 (4.06)	105.4 (2.76)
Median	104.0	104.5	103.0	106.0
Median Range	95; 109	100; 108	95; 108	101; 109
Visit 3 – 3 hrs post-dose, n	14	7	8	7
Mean (SD)	104.0 (4.64)	103.3 (2.29)	103.3 (2.05)	106.4 (2.64)
Median	105.5	103.0	103.0	107.0
Median Range	95; 110	100; 107	99; 106	103; 110
Visit 4, n	13	8	8	6
Mean (SD)	102.8 (3.53)	103.6 (4.44)	104.3 (3.11)	104.0 (2.10)
Median	103.0	102.5	104.5	104.5
Median Range	96; 109	99; 114	100; 108	101; 106
Visit 5, n	14	8	9	6
Mean (SD)	102.9 (3.06)	102.3 (2.25)	105.2 (2.59)	102.0 (3.90)
Median	102.5	102.5	105.0	102.0
Median Range	96; 108	99; 106	101; 109	96; 107
Visit 6, n	14	7	8	6
Mean (SD)	102.9 (3.32)	102.1 (2.67)	103.4 (4.78)	102.2 (3.43)
Median	104.0	103.0	104.0	102.5
Median Range	95; 107	98; 106	95; 110	97; 106
Visit 7, n	14	7	8	6
Mean (SD)	102.6 (3.92)	103.0 (3.32)	104.6 (2.50)	105.0 (2.37)
Median	103.0	104.0	104.0	105.0
Median Range	96; 109	98; 107	102; 109	102; 108
Early Withdrawal, n	2	0	0	0
Mean (SD)	108.5 (6.36)	0	0	0
Median	108.5	0	0	0
Median Range	104; 113	0	0	0
CARBON DIOXIDE CONTENT/BICARBONATE (MMOL/L)				
Visit 1 – Pre-dose, n	16	8	9	8
Mean (SD)	19.1 (2.91)	19.4 (3.11)	17.4 (2.55)	17.8 (2.43)
Median	20.0	19.5	17.0	16.5
Median Range	14; 22	15; 25	15; 22	16; 22
Visit 1 – 24 hrs post-dose, n	15	7	7	7
Mean (SD)	19.7 (2.92)	18.4 (2.23)	19.6 (2.51)	18.6 (2.70)
Median	20.0	19.0	19.0	18.0
Median Range	12; 23	15; 21	16; 23	15; 23

Visit 2, n	14	7	9	8
Mean (SD)	19.6 (2.65)	19.3 (2.50)	19.6 (2.96)	18.4 (3.85)
Median	19.5	20.0	20.0	18.0
Median Range	16; 26	15; 22	15; 24	13; 24
Visit 3 – Pre-dose, n	13	8	8	7
Mean (SD)	20.1 (2.14)	20.9 (2.59)	19.6 (2.39)	19.0 (3.51)
Median	20.0	20.5	20.5	18.0
Median Range	16; 24	18; 26	14; 21	14; 24
Visit 3 – 3 hrs post-dose, n	14	7	8	7
Mean (SD)	19.4 (2.68)	20.9 (1.35)	20.8 (1.98)	19.6 (2.23)
Median	20.0	21.0	21.5	19.0
Median Range	13; 23	19; 23	17; 23	17; 23
Visit 4, n	13	8	8	6
Mean (SD)	20.4 (2.90)	20.0 (3.70)	20.0 (2.67)	20.7 (4.97)
Median	20.0	20.5	20.0	20.5
Median Range	17; 26	12; 25	16; 23	12; 26
Visit 5, n	14	8	9	6
Mean (SD)	20.9 (3.08)	21.1 (2.03)	19.6 (1.81)	24.8 (2.32)
Median	21.5	21.0	19.0	24.0
Median Range	13; 26	18; 25	17; 22	23; 29
Visit 6, n	14	7	8	5
Mean (SD)	21.6 (2.95)	22.7 (3.90)	21.1 (2.10)	22.8 (3.35)
Median	22.5	23.0	21.0	23.0
Median Range	17; 27	16; 28	18; 24	19; 28
Visit 7, n	14	8	8	6
Mean (SD)	21.4 (4.13)	21.9 (2.64)	21.6 (1.77)	21.0 (3.63)
Median	23.0	22.0	22.0	21.0
Median Range	14; 27	17; 25	19; 24	15; 26
Early Withdrawal, n	2	0	0	0
Mean (SD)	21.5 (7.78)	0	0	0
Median	21.5	0	0	0
Median Range	16; 27	0	0	0
CREATININE (UMOL/L)				
Visit 1 – Pre-dose, n	15	8	9	8
Mean (SD)	62.9 (12.98)	74.0 (24.80)	79.9 (36.84)	71.9 (16.97)
Median	58.0	63.0	65.0	68.0
Median Range	52; 98	60; 133	53; 173	52; 105
Visit 1 – 24 hrs post-dose, n	15	7	7	7
Mean (SD)	65.0 (14.32)	69.1 (26.31)	66.6 (16.40)	78.0 (15.56)
Median	61.0	60.0	62.0	73.0
Median Range	50; 93	49; 124	53; 101	57; 106
Visit 2, n	14	7	9	8
Mean (SD)	70.6 (16.23)	68.9 (14.38)	79.4 (34.86)	71.9 (15.14)
Median	64.0	67.0	63.0	71.0
Median Range	56; 117	53; 94	53; 166	55; 102
Visit 3 – Pre-dose, n	13	8	8	7
Mean (SD)	77.2 (21.94)	82.3 (25.69)	84.4 (44.14)	87.4 (44.15)
Median	70.0	76.0	68.5	71.0
Median Range	50; 119	58; 141	55; 189	61; 186
Visit 3 – 3 hrs post-dose, n	13	7	8	7
Mean (SD)	76.1 (19.41)	73.6 (8.00)	88.6 (44.15)	93.0 (47.17)
Median	71.0	73.0	70.0	80.0
Median Range	50; 110	61; 86	56; 188	57; 194
Visit 4, n	13	8	8	6

Mean (SD)	81.4 (25.90)	86.3 (28.87)	89.4 (37.70)	87.3 (16.37)
Median	71.0	77.5	79.5	84.0
Median Range	57; 151	62; 150	57; 178	71; 115
Visit 5, n	14	8	8	6
Mean (SD)	81.5 (20.91)	84.1 (30.97)	92.8 (41.82)	79.2 (24.81)
Median	81.0	72.0	75.5	78.0
Median Range	55; 135	61; 150	55; 178	44; 121
Visit 6, n	14	7	8	6
Mean (SD)	78.5 (17.94)	78.9 (18.98)	112.6 (81.94)	88.7 (31.78)
Median	81.0	80.0	74.5	78.5
Median Range	50; 102	62; 115	60; 300	71; 153
Visit 7, n	14	8	8	6
Mean (SD)	77.9 (17.83)	81.1 (25.95)	84.1 (31.32)	75.7 (21.06)
Median	79.0	74.0	73.0	71.0
Median Range	57; 113	62; 141	62; 160	52; 112
Early Withdrawal, n	2	0	0	0
Mean (SD)	54.0 (1.41)	0	0	0
Median	54.0	0	0	0
Median Range	53; 55	0	0	0
GAMMA GLUTAMYLTRANSFERASE (IU/L)				
Visit 1 – Pre-dose, n	16	8	9	8
Mean (SD)	49.6 (29.33)	21.5 (8.62)	25.2 (16.99)	32.8 (16.33)
Median	47.5	17.5	18.0	30.5
Median Range	11; 110	13; 33	12; 62	16; 69
Visit 1 – 24 hrs post-dose, n	15	7	7	7
Mean (SD)	44.9 (28.74)	18.1 (5.98)	25.3 (22.14)	32.0 (14.75)
Median	45.0	17.0	17.0	27.0
Median Range	8; 107	11; 27	12; 74	18; 61
Visit 2, n	14	7	9	8
Mean (SD)	63.9 (49.59)	26.9 (12.06)	28.2 (22.24)	32.5 (14.80)
Median	45.0	23.0	22.0	27.0
Median Range	16; 190	13; 43	13; 82	16; 56
Visit 3 – Pre-dose, n	13	8	8	7
Mean (SD)	62.5 (49.73)	26.1 (9.70)	29.4 (26.33)	26.7 (8.99)
Median	46.0	24.5	21.5	22.0
Median Range	13; 193	14; 42	14; 93	19; 44
Visit 3 – 3 hrs post-dose, n	14	7	8	7
Mean (SD)	59.8 (48.76)	25.9 (6.77)	28.1 (24.09)	27.0 (7.28)
Median	42.0	26.0	21.0	24.0
Median Range	13; 188	18; 36	13; 86	20; 40
Visit 4, n	13	8	8	6
Mean (SD)	68.2 (50.57)	23.3 (11.91)	24.3 (13.31)	29.0 (9.36)
Median	45.0	19.0	20.5	25.5
Median Range	13; 177	10; 46	13; 54	20; 45
Visit 5, n	14	8	9	6
Mean (SD)	42.0 (26.07)	26.6 (19.73)	31.3 (33.51)	39.2 (21.12)
Median	35.5	19.5	22.0	34.5
Median Range	11; 112	11; 73	5; 115	18; 71
Visit 6, n	14	7	8	6
Mean (SD)	41.2 (31.08)	26.9 (22.31)	39.1 (51.75)	46.5 (30.15)
Median	30.0	21.0	17.5	34.0
Median Range	10; 132	11; 76	14; 164	23; 101
Visit 7, n	14	8	8	6
Mean (SD)	39.4 (27.58)	20.8 (5.55)	32.5 (20.47)	55.2 (36.65)

Median	30.0	21.5	20.5	48.0
Median Range	12; 118	10; 27	14; 58	21; 120
Early Withdrawal, n	2	0	0	0
Mean (SD)	71.0 (9.90)	0	0	0
Median	71.0	0	0	0
Median Range	64; 78	0	0	0
GLUCOSE (MMOL/L)				
Visit 1 – Pre-dose, n	16	8	9	8
Mean (SD)	6.45 (1.434)	6.90 (1.821)	7.43 (3.125)	8.13 (3.660)
Median	6.30	6.35	7.40	7.80
Median Range	4.6; 8.5	5.0; 9.7	2.3; 13.4	4.0; 15.7
Visit 1 – 24 hrs post-dose, n	15	7	7	7
Mean (SD)	7.61 (3.085)	6.83 (1.502)	7.46 (2.053)	9.71 (3.328)
Median	7.70	6.80	8.20	9.60
Median Range	2.7; 14.7	5.3; 9.4	4.7; 10.1	5.7; 14.8
Visit 2, n	14	7	9	8
Mean (SD)	6.91 (1.963)	6.57 (1.521)	7.71 (3.035)	6.54 (2.452)
Median	6.05	7.60	6.80	5.50
Median Range	4.8; 10.3	4.3; 7.9	3.5; 13.0	3.9; 11.2
Visit 3 – Pre-dose, n	13	8	8	6
Mean (SD)	7.31 (3.168)	6.53 (1.085)	7.71 (3.283)	7.00 (1.710)
Median	6.70	6.50	6.50	6.65
Median Range	4.5; 16.3	5.2; 8.2	4.9; 14.5	4.7; 9.2
Visit 3 – 3 hrs post-dose, n	13	7	8	7
Mean (SD)	7.61 (3.485)	6.61 (1.553)	7.04 (2.436)	6.67 (2.862)
Median	6.30	6.50	6.75	6.30
Median Range	4.9; 18.4	4.8; 8.9	3.7; 11.4	3.4; 12.6
Visit 4, n	13	8	8	6
Mean (SD)	5.66 (0.689)	5.66 (0.878)	7.41 (3.630)	6.67 (3.147)
Median	5.70	5.55	6.15	5.80
Median Range	4.6; 7.2	4.4; 7.0	5.5; 16.3	4.1; 12.8
Visit 5, n	14	8	9	6
Mean (SD)	5.56 (1.311)	6.13 (2.661)	6.91 (2.703)	6.17 (1.472)
Median	5.30	5.35	5.80	6.65
Median Range	4.0; 8.8	4.1; 12.3	4.9; 12.8	4.3; 7.7
Visit 6, n	14	7	8	6
Mean (SD)	6.03 (1.906)	6.19 (2.051)	6.38 (1.150)	6.30 (1.840)
Median	5.65	5.40	6.30	5.60
Median Range	2.9; 9.7	3.9; 9.8	4.4; 8.1	4.3; 9.1
Visit 7, n	14	8	8	6
Mean (SD)	6.09 (1.491)	6.18 (2.180)	6.11 (1.600)	6.47 (1.160)
Median	6.00	5.45	5.60	6.30
Median Range	4.3; 9.5	3.7; 10.2	4.7; 9.8	5.3; 8.5
Early Withdrawal, n	2	0	0	0
Mean (SD)	8.55 (0.636)	0	0	0
Median	8.55	0	0	0
Median Range	8.1; 9.0	0	0	0
POTASSIUM (MMOL/L)				
Visit 1 – Pre-dose, n	16	8	9	8
Mean (SD)	4.14 (0.532)	4.10 (0.273)	4.00 (0.495)	3.94 (0.400)
Median	4.00	4.15	3.90	3.95
Median Range	3.5; 5.5	3.7; 4.4	3.4; 4.9	3.4; 4.7
Visit 1 – 24 hrs post-dose, n	15	7	7	7

Mean (SD)	4.45 (1.380)	4.04 (0.364)	4.00 (0.412)	4.10 (0.153)
Median	4.10	3.90	4.00	4.10
Median Range	3.5; 9.0	3.6; 4.6	3.4; 4.6	3.9; 4.3
Visit 2, n	14	7	9	8
Mean (SD)	4.11 (0.401)	4.04 (0.223)	4.11 (0.523)	3.98 (0.337)
Median	4.15	4.10	3.80	4.00
Median Range	3.1; 4.8	3.7; 4.3	3.5; 5.0	3.5; 4.5
Visit 3 – Pre-dose, n	13	8	8	7
Mean (SD)	4.32 (0.788)	4.25 (0.293)	4.64 (0.453)	4.36 (0.796)
Median	4.30	4.20	4.50	4.20
Median Range	3.2; 6.6	3.9; 4.8	4.0; 5.3	3.3; 5.9
Visit 3 – 3 hrs post-dose, n	14	7	8	7
Mean (SD)	4.34 (0.676)	4.11 (0.186)	4.40 (0.370)	4.26 (0.251)
Median	4.20	4.20	4.40	4.20
Median Range	3.3; 5.8	3.9; 4.4	3.8; 5.1	4.1; 4.8
Visit 4, n	13	8	8	6
Mean (SD)	4.25 (0.369)	4.14 (0.283)	4.08 (0.369)	4.25 (0.084)
Median	4.30	4.15	3.95	4.30
Median Range	3.4; 4.7	3.6; 4.6	3.7; 4.8	4.1; 4.3
Visit 5, n	14	8	9	6
Mean (SD)	4.33 (0.644)	4.09 (0.445)	4.33 (0.671)	4.25 (0.423)
Median	4.30	4.00	4.20	4.20
Median Range	3.2; 5.6	3.6; 5.0	3.6; 5.9	3.8; 4.9
Visit 6, n	14	7	8	5
Mean (SD)	4.23 (0.408)	3.96 (0.479)	4.38 (0.534)	4.22 (0.303)
Median	4.15	4.00	4.35	4.20
Median Range	3.6; 5.1	3.5; 4.8	3.4; 5.3	3.8; 4.6
Visit 7, n	14	7	8	6
Mean (SD)	4.24 (0.418)	4.01 (0.515)	4.33 (0.471)	4.13 (0.250)
Median	4.20	3.90	4.45	4.15
Median Range	3.6; 4.9	3.2; 4.6	3.2; 4.7	3.8; 4.4
Early Withdrawal, n	2	0	0	0
Mean (SD)	4.10 (0.141)	0	0	0
Median	4.10	0	0	0
Median Range	4.0; 4.2	0	0	0
SODIUM (MMOL/L)				
Visit 1 – Pre-dose, n	16	8	9	8
Mean (SD)	139.2 (2.86)	140.3 (1.58)	140.6 (3.84)	137.5 (4.11)
Median	138.0	140.0	140.0	137.5
Median Range	135; 145	138; 143	137; 150	131; 144
Visit 1 – 24 hrs post-dose, n	15	7	7	7
Mean (SD)	139.2 (3.86)	139.1 (1.77)	139.4 (4.35)	138.9 (3.34)
Median	139.0	139.0	138.0	139.0
Median Range	134; 149	137; 142	136; 149	133; 143
Visit 2, n	14	7	9	8
Mean (SD)	137.9 (4.21)	141.3 (1.98)	138.8 (2.05)	139.5 (2.27)
Median	138.0	141.0	138.0	139.5
Median Range	128; 146	139; 145	136; 143	136; 143
Visit 3 – Pre-dose, n	13	8	8	7
Mean (SD)	138.4 (3.57)	140.0 (1.85)	138.0 (1.85)	139.6 (1.72)
Median	139.0	140.0	138.5	139.0
Median Range	130; 144	137; 143	135; 140	138; 142
Visit 3 – 3 hrs post-dose, n	14	7	8	7
Mean (SD)	137.6 (3.65)	139.3 (1.60)	138.9 (1.13)	139.1 (1.21)

Median	139.0	140.0	138.5	139.0
Median Range	129; 142	136; 141	138; 141	138; 141
Visit 4, n	13	8	8	6
Mean (SD)	137.5 (4.68)	140.1 (1.13)	139.8 (2.12)	140.0 (1.55)
Median	138.0	140.0	139.5	140.5
Median Range	129; 144	139; 142	137; 143	137; 141
Visit 5, n	14	8	9	6
Mean (SD)	139.4 (2.47)	140.4 (1.60)	139.6 (1.88)	139.7 (2.16)
Median	140.0	140.0	140.0	139.5
Median Range	135; 144	138; 143	137; 142	137; 143
Visit 6, n	14	7	8	6
Mean (SD)	138.9 (3.11)	138.9 (2.54)	139.0 (2.62)	139.2 (1.72)
Median	139.5	140.0	139.0	139.5
Median Range	133; 143	134; 141	135; 142	136; 141
Visit 7, n	14	7	8	6
Mean (SD)	138.9 (3.71)	140.9 (3.02)	140.6 (2.26)	141.7 (2.34)
Median	140.0	141.0	140.0	141.0
Median Range	131; 146	136; 145	137; 144	139; 146
Early Withdrawal, n	2	0	0	0
Mean (SD)	143.5 (7.78)	0	0	0
Median	143.5	0	0	0
Median Range	138; 149	0	0	0
TOTAL PROTEIN (G/L)				
Visit 1 – Pre-dose, n	15	8	9	8
Mean (SD)	64.9 (7.39)	62.8 (5.82)	61.9 (5.95)	64.3 (9.38)
Median	67.0	61.0	62.0	65.0
Median Range	43; 73	54; 72	55; 72	45; 74
Visit 1 – 24 hrs post-dose, n	15	7	7	7
Mean (SD)	64.1 (6.94)	55.7 (7.57)	60.3 (6.70)	64.3 (6.92)
Median	64.0	58.0	59.0	63.0
Median Range	51; 76	46; 65	53; 71	55; 74
Visit 2, n	14	7	9	8
Mean (SD)	67.1 (7.12)	64.7 (7.95)	63.4 (7.52)	65.6 (9.32)
Median	67.0	67.0	62.0	69.0
Median Range	55; 78	52; 75	54; 80	48; 78
Visit 3 – Pre-dose, n	13	8	8	7
Mean (SD)	67.8 (5.54)	66.8 (6.18)	66.6 (7.56)	63.9 (8.30)
Median	67.0	68.0	68.5	63.0
Median Range	59; 76	55; 74	52; 76	49; 73
Visit 3 – 3 hrs post-dose, n	14	7	8	7
Mean (SD)	65.4 (6.49)	65.4 (5.16)	66.0 (5.48)	63.3 (6.68)
Median	65.0	66.0	66.0	65.0
Median Range	56; 78	59; 72	55; 72	51; 70
Visit 4, n	13	8	8	6
Mean (SD)	69.2 (3.32)	68.9 (5.74)	69.1 (3.23)	69.0 (7.07)
Median	69.0	70.5	69.5	69.5
Median Range	64; 76	59; 78	65; 73	58; 77
Visit 5, n	14	8	9	6
Mean (SD)	72.3 (3.24)	69.3 (6.98)	69.2 (5.59)	67.8 (10.03)
Median	72.0	70.0	69.0	68.5
Median Range	67; 77	56; 79	61; 78	51; 79
Visit 6, n	14	7	8	6
Mean (SD)	70.5 (3.65)	69.0 (6.51)	71.0 (6.61)	73.7 (4.89)
Median	71.0	72.0	72.0	75.5

Median Range	65; 77	57; 76	60; 79	65; 78
Visit 7, n	14	8	8	6
Mean (SD)	70.0 (3.53)	68.8 (4.46)	72.4 (8.47)	72.3 (4.76)
Median	70.5	69.0	71.0	73.0
Median Range	63; 75	59; 74	60; 88	66; 79
Early Withdrawal, n	2	0	0	0
Mean (SD)	58.5 (7.78)	0	0	0
Median	58.5	0	0	0
Median Range	53; 64	0	0	0
UREA/BUN (MMOL/L)				
Visit 1 – Pre-dose, n	16	8	9	8
Mean (SD)	5.05 (1.742)	4.75 (1.457)	5.37 (3.449)	5.44 (2.273)
Median	4.90	4.45	4.90	4.75
Median Range	2.5; 7.5	3.0; 7.5	2.1; 13.0	2.8; 9.5
Visit 1 – 24 hrs post-dose, n	15	7	7	7
Mean (SD)	5.10 (1.813)	4.24 (1.452)	3.96 (1.220)	5.79 (1.340)
Median	4.60	3.50	3.50	5.90
Median Range	2.3; 9.5	3.0; 7.0	2.4; 6.0	3.5; 8.0
Visit 2, n	14	7	9	8
Mean (SD)	5.41 (1.922)	5.17 (1.738)	5.42 (2.798)	5.31 (1.387)
Median	5.05	4.50	4.60	5.10
Median Range	2.9; 9.8	3.8; 7.9	3.2; 12.2	3.6; 7.4
Visit 3 – Pre-dose, n	13	8	8	7
Mean (SD)	5.75 (2.152)	6.85 (2.637)	5.50 (2.757)	5.09 (1.192)
Median	5.20	6.50	4.95	4.60
Median Range	3.1; 10.1	4.3; 11.0	3.1; 12.0	3.6; 7.0
Visit 3 – 3 hrs post-dose, n	14	7	8	6
Mean (SD)	5.72 (1.992)	6.29 (2.197)	5.84 (2.675)	5.22 (1.019)
Median	5.15	5.80	5.50	4.85
Median Range	3.0; 10.1	4.6; 11.0	3.2; 12.1	4.3; 7.0
Visit 4, n	13	8	8	6
Mean (SD)	5.78 (2.452)	7.75 (3.780)	6.43 (3.600)	5.17 (1.480)
Median	4.80	5.95	5.60	4.75
Median Range	2.9; 10.5	4.5; 15.7	2.1; 12.6	3.6; 7.9
Visit 5, n	14	8	9	6
Mean (SD)	5.59 (2.173)	6.44 (1.708)	5.63 (3.382)	5.78 (1.327)
Median	5.50	6.30	4.20	5.15
Median Range	2.7; 10.0	4.5; 9.3	2.2; 11.3	4.6; 8.0
Visit 6, n	14	7	8	6
Mean (SD)	5.51 (1.957)	5.23 (1.928)	6.46 (5.762)	6.93 (2.516)
Median	4.60	4.40	4.85	6.90
Median Range	3.6; 10.2	3.3; 8.0	2.0; 19.9	4.3; 10.0
Visit 7, n	14	8	8	6
Mean (SD)	6.24 (3.779)	5.96 (1.986)	5.68 (2.042)	7.13 (1.801)
Median	5.15	5.55	5.05	7.50
Median Range	3.0; 17.7	3.5; 9.0	3.5; 10.4	4.0; 9.0
Early Withdrawal, n	2	0	0	0
Mean (SD)	9.05 (6.293)	0	0	0
Median	9.05	0	0	0
Median Range	4.6; 13.5	0	0	0
URIC ACID (UMOL/L)				
Visit 1 – Pre-dose, n	15	8	9	8
Mean (SD)	298.3 (75.42)	326.3 (68.14)	300.2 (132.60)	333.5 (109.38)

Median	300.0	336.5	279.0	326.0
Median Range	190; 436	226; 422	111; 511	209; 547
Visit 1 – 24 hrs post-dose, n	15	7	7	6
Mean (SD)	296.1 (76.34)	300.4 (94.05)	229.7 (78.41)	316.3 (74.64)
Median	297.0	320.0	230.0	323.0
Median Range	187; 426	157; 442	134; 370	212; 420
Visit 2, n	14	7	9	8
Mean (SD)	317.6 (118.40)	345.9 (131.01)	266.3 (120.18)	309.8 (61.29)
Median	295.5	330.0	283.0	291.5
Median Range	160; 590	182; 545	45; 475	242; 411
Visit 3 – Pre-dose, n	13	8	8	6
Mean (SD)	343.5 (115.88)	373.5 (104.81)	299.3 (124.90)	350.0 (72.45)
Median	320.0	360.0	294.5	375.5
Median Range	235; 655	246; 510	163; 537	234; 415
Visit 3 – 3 hrs post-dose, n	13	7	8	7
Mean (SD)	326.3 (117.07)	360.6 (103.38)	296.5 (122.81)	336.7 (78.17)
Median	294.0	307.0	301.0	360.0
Median Range	227; 658	243; 500	150; 520	207; 420
Visit 4, n	13	8	8	6
Mean (SD)	370.2 (116.77)	452.0 (153.49)	353.3 (151.06)	339.3 (96.54)
Median	358.0	420.0	359.5	347.5
Median Range	193; 569	300; 798	157; 586	206; 475
Visit 5, n	14	8	8	6
Mean (SD)	355.6 (120.60)	377.8 (115.03)	351.5 (129.98)	410.3 (120.32)
Median	361.5	376.5	354.0	411.5
Median Range	193; 537	164; 562	146; 541	260; 610
Visit 6, n	14	7	8	6
Mean (SD)	341.1 (75.64)	355.9 (103.25)	374.3 (183.88)	485.8 (181.30)
Median	349.5	360.0	335.0	467.0
Median Range	224; 478	193; 480	167; 746	280; 760
Visit 7, n	14	8	8	6
Mean (SD)	362.4 (123.12)	359.8 (90.59)	300.3 (72.91)	434.0 (218.10)
Median	327.0	379.0	317.5	388.5
Median Range	202; 677	210; 475	184; 390	191; 810
Early Withdrawal, n	2	0	0	0
Mean (SD)	218.5 (26.16)	0	0	0
Median	218.5	0	0	0
Median Range	200; 237	0	0	0

Immunogenicity Results (All Subjects Population)				
	Placebo N=17	GSK249320 1 mg/kg N=8	GSK249320 5 mg/kg N=9	GSK249320 15 mg/kg N=8
Anti-GSK249320 Positive Results	n (%)	n (%)	n (%)	n (%)
Visit 1 Day 1	0	0	1/9 (11)	0
Visit 2 Day 5	0	0	0	0
Visit 3 Day 10	0	1/8 (13)	1/9 (11)	0
Visit 4 Day 30	0	0	1/9 (11)	0
Visit 5 Day 60	0	0	1/8 (13)	0
Visit 6 Day 90	0	0	0	0
Visit 7 Day 112	0	0	0	0

Anti-GSK249320 Positive Subject Response (All Subjects Population)				
Subject ID	Dose (mg/kg)/	Timepoint	Binding antibodies	Neutralizing antibodies

	Placebo	(Day)	Confirmed Positive	Titer	
590006	5 mg/kg	Pre-Dose	No		
590006	5 mg/kg	Day 5	No		
590006	5 mg/kg	Day 10	Yes	32	NA
590006	5 mg/kg	Day 30	Yes	80	NA
590006	5 mg/kg	Day 60	Yes	64	NA
590006	5 mg/kg	Day 90	No		
590006	5 mg/kg	Day 112	No		
600003	1 mg/kg	Pre-Dose	No		
600003	1 mg/kg	Day 5	No		
600003	1 mg/kg	Day 10	Yes	4	NA
600003	1 mg/kg	Day 30	No		
600003	1 mg/kg	Day 60	No		
600003	1 mg/kg	Day 90	No		
600003	1 mg/kg	Day 112	No		
600006	5 mg/kg	Pre-Dose	Yes	600	NA
600006	5 mg/kg	Day 5	No		
600006	5 mg/kg	Day 10	No		
600006	5 mg/kg	Day 30	No		
600006	5 mg/kg	Day 60	No		
600006	5 mg/kg	Day 90	No		
600006	5 mg/kg	Day 112	No		

Summary Statistics of Derived Plasma GSK249320 Non Compartmental Pharmacokinetic Parameters (PK Population)¹

Parameter	GSK2493 20 Treatment	N	Dose	n	Mean	SD	Median	Min.	Max.
AUC(0-inf) (hr*mg/mL)	1 mg/kg	8	DOSE 1	8	15.20	4.049	14.11	10.1	21.7
	5 mg/kg	9	DOSE 1	8	71.01	14.426	72.11	52.8	88.7
	15 mg/kg	8	DOSE 1	7	192.88	75.413	188.23	92.5	340.5
AUC(0-t) (hr*mg/mL)	1 mg/kg	8	DOSE 1	8	4.12	0.643	4.10	3.1	5.1
			DOSE 2	8	25.64	7.272	26.99	16.3	33.8
	5 mg/kg	9	DOSE 1	8	17.25	3.704	18.46	10.2	21.2
			DOSE 2	8	118.38	28.885	116.29	73.9	159.1
	15 mg/kg	8	DOSE 1	8	51.07	18.719	55.77	10.3	70.6
			DOSE 2	7	365.63	83.891	362.38	239.4	517.4
Cmax (ug/mL)	1 mg/kg	8	DOSE 1	8	38.62	8.832	37.13	30.3	56.6
			DOSE 2	8	53.06	17.650	51.29	31.9	90.6
	5 mg/kg	9	DOSE 1	8	157.42	25.814	159.38	118.0	193.5
			DOSE 2	8	215.71	30.617	203.29	183.9	275.7
	15 mg/kg	8	DOSE 1	8	508.20	74.468	477.89	443.2	650.9
			DOSE 2	7	756.98	178.150	723.01	587.8	1080.7
Ct (ug/mL)	1 mg/kg	8	DOSE 1	8	14.9528	3.63064	13.6862	10.700	19.803
			DOSE 2	8	0.6647	0.35900	0.7090	0.163	1.062
	5 mg/kg	9	DOSE 1	9	59.3422	22.10706	64.7016	8.970	82.667
			DOSE 2	9	6.8148	4.04066	6.7678	0.352	13.386
	15 mg/kg	8	DOSE 1	8	192.1709	92.75262	184.5448	56.810	390.028
			DOSE 2	7	22.1555	17.84140	14.9789	8.026	60.512
tmax (hr)	1 mg/kg	8	DOSE 1	8	2.723	3.8135	1.025	1.00	12.00
			DOSE 2	8	2.013	1.0562	2.050	1.00	3.00
	5 mg/kg	9	DOSE 1	9	1.807	1.7017	1.080	1.00	6.00
			DOSE 2	9	1.618	1.1276	1.030	1.00	4.08
	15 mg/kg	8	DOSE 1	8	1.885	1.8745	1.040	0.75	6.17
			DOSE 2	7	1.885	1.8745	1.040	0.75	6.17

			DOSE 2	7	1.874	1.0792	1.080	0.93	3.08
t _{last} (hr)	1 mg/kg	8	DOSE 1	8	207.43	26.247	201.12	176.8	243.4
			DOSE 2	8	2901.11	144.034	2914.33	2642.9	3066.1
	5 mg/kg	9	DOSE 1	9	192.67	39.911	208.95	90.3	215.5
			DOSE 2	9	2539.06	418.783	2491.17	1972.7	3554.5
	15 mg/kg	8	DOSE 1	8	205.47	83.950	213.53	24.7	288.2
			DOSE 2	7	2403.84	141.350	2426.50	2160.9	2617.6
t _{1/2} (day)	1 mg/kg	8	DOSE 2	8	21.11	3.121	21.44	16.6	26.2
	5 mg/kg	9	DOSE 2	9	24.01	5.240	22.80	16.2	32.2
	15 mg/kg	8	DOSE 2	7	24.01	8.551	21.54	17.3	42.3
λ-z (1/hr)	1 mg/kg	8	DOSE 1	8	0.00138	0.000191	0.00135	0.0011	0.0017
			DOSE 2	8	0.00139	0.000207	0.00135	0.0011	0.0017
	5 mg/kg	9	DOSE 1	9	0.00126	0.000292	0.00130	0.0009	0.0018
			DOSE 2	9	0.00126	0.000281	0.00127	0.0009	0.0018
	15 mg/kg	8	DOSE 1	7	0.00130	0.000327	0.00130	0.0007	0.0017
			DOSE 2	7	0.00130	0.000327	0.00134	0.0007	0.0017
CL (mL/hr/Kg)	1 mg/kg	8	DOSE 1	8	0.0700	0.01835	0.0710	0.046	0.099
	5 mg/kg	9	DOSE 1	9	0.0750	0.01545	0.0727	0.056	0.095
	15 mg/kg	8	DOSE 1	7	0.0886	0.03652	0.0797	0.044	0.162

1. Summary statistics of Non Compartmental Pharmacokinetic Parameters were comparable with those obtained from the Compartmental Pharmacokinetic Population Analysis.

Summary of Mixed Model Repeated Measures Analysis of Change in Mean Gait Velocity (All Subjects Population)				
Visit/ Comparison	Adjusted Mean		Treatment Difference (SE)	95% CI
	GSK249320	Placebo		
Visit 4 Day 30				
GSK249320 1 mg/kg vs placebo	0.44	-0.01	0.45 (0.231)	(-0.03, 0.92)
GSK249320 5 mg/kg vs placebo	0.68	-0.01	0.69 (0.214)	(0.25, 1.13)
GSK249320 15 mg/kg vs placebo	0.29	-0.01	0.30 (0.246)	(-0.20, 0.80)
Visit 5 Day 60				
GSK249320 1 mg/kg vs placebo	0.59	0.24	0.35 (0.292)	(-0.24, 0.95)
GSK249320 5 mg/kg vs placebo	0.76	0.24	0.52 (0.279)	(-0.05, 1.09)
GSK249320 15 mg/kg vs placebo	0.28	0.24	0.04 (0.319)	(-0.61, 0.69)
Visit 6 Day 90				
GSK249320 1 mg/kg vs placebo	0.84	0.21	0.63 (0.235)	(0.15, 1.11)
GSK249320 5 mg/kg vs placebo	0.61	0.21	0.40 (0.225)	(-0.06, 0.86)
GSK249320 15 mg/kg vs placebo	0.45	0.21	0.24 (0.259)	(-0.29, 0.77)
Visit 7 Day 112				
GSK249320 1 mg/kg vs placebo	0.97	0.36	0.61 (0.251)	(0.10, 1.12)
GSK249320 5 mg/kg vs placebo	0.94	0.36	0.59 (0.242)	(0.09, 1.08)
GSK249320 15 mg/kg vs placebo	0.53	0.36	0.17 (0.277)	(-0.39, 0.73)
Summary of Mixed Model Repeated Measures Analysis of Change in Total Berg Balance Scale (BBS) (All Subjects Population)				
Visit/ Comparison	Adjusted Mean		Treatment Difference (SE)	95% CI
	GSK249320	Placebo		
Visit 4 Day 30				
GSK249320 1 mg/kg vs placebo	16.45	6.89	9.56 (4.981)	(-0.60, 19.71)
GSK249320 5 mg/kg vs placebo	15.36	6.89	8.47 (4.801)	(-1.32, 18.26)
GSK249320 15 mg/kg vs placebo	6.98	6.89	0.09 (5.470)	(-11.1, 11.24)
Visit 5 Day 60				
GSK249320 1 mg/kg vs placebo	22.40	10.81	11.58 (5.631)	(0.01, 23.15)
GSK249320 5 mg/kg vs placebo	19.58	10.81	8.77 (5.411)	(-2.35, 19.89)
GSK249320 15 mg/kg vs placebo	11.31	10.81	0.49 (6.195)	(-12.2, 13.21)
Visit 6 Day 90				

GSK249320 1 mg/kg vs placebo	23.32	13.66	9.66 (5.351)	(-1.34, 20.66)
GSK249320 5 mg/kg vs placebo	21.11	13.66	7.45 (5.198)	(-3.22, 18.13)
GSK249320 15 mg/kg vs placebo	3.03	13.66	-10.63 (5.959)	(-22.9, 1.60)
Visit 7 Day 112				
GSK249320 1 mg/kg vs placebo	24.32	14.74	9.59 (6.134)	(-3.07, 22.24)
GSK249320 5 mg/kg vs placebo	20.63	14.74	5.89 (5.948)	(-6.37, 18.15)
GSK249320 15 mg/kg vs placebo	11.62	14.74	-3.11 (6.768)	(-17.1, 10.84)
Summary of Mixed Model Repeated Measures Analysis for Change in Fugl-Meyer (FM) Motor Assessment:Total Score (All Subjects Population)				
Visit/ Comparison	Adjusted Mean		Treatment Difference (SE)	95% CI
	GSK249320	Placebo		
Visit 4 Day 30				
GSK249320 1 mg/kg vs placebo	8.10	9.58	-1.47 (7.047)	(-15.81, 12.86)
GSK249320 5 mg/kg vs placebo	19.44	9.58	9.86 (6.852)	(-4.08, 23.80)
GSK249320 15 mg/kg vs placebo	4.17	9.58	-5.40 (7.376)	(-20.41, 9.60)
Visit 7 Day 112				
GSK249320 1 mg/kg vs placebo	16.60	19.01	-2.40 (10.040)	(-22.87, 18.07)
GSK249320 5 mg/kg vs placebo	24.03	19.01	5.03 (10.310)	(-15.95, 26.00)
GSK249320 15 mg/kg vs placebo	8.94	19.01	-10.07 (10.916)	(-32.29, 12.15)
Summary of Mixed Model Repeated Measures Analysis for Change in Total Box and Blocks Transferred on Affected Side (All Subjects Population)				
Visit/ Comparison	Adjusted Mean		Treatment Difference (SE)	95% CI
	GSK249320	Placebo		
Visit 4 Day 30				
GSK249320 1 mg/kg vs placebo	8.61	8.48	0.13 (5.147)	(-10.4, 10.61)
GSK249320 5 mg/kg vs placebo	11.24	8.48	2.75 (5.157)	(-7.75, 13.26)
GSK249320 15 mg/kg vs placebo	13.34	8.48	4.85 (5.409)	(-6.17, 15.88)
Visit 5 Day 60				
GSK249320 1 mg/kg vs placebo	14.61	13.41	1.20 (6.504)	(-12.1, 14.45)
GSK249320 5 mg/kg vs placebo	15.46	13.41	2.05 (6.426)	(-11.0, 15.12)
GSK249320 15 mg/kg vs placebo	11.20	13.41	-2.22 (6.820)	(-16.1, 11.68)
Visit 6 Day 90				
GSK249320 1 mg/kg vs placebo	16.11	15.48	0.63 (6.664)	(-12.9, 14.18)
GSK249320 5 mg/kg vs placebo	16.52	15.48	1.03 (6.595)	(-12.4, 14.43)
GSK249320 15 mg/kg vs placebo	14.54	15.48	-0.95 (7.020)	(-15.2, 13.32)
Visit 7 Day 112				
GSK249320 1 mg/kg vs placebo	18.74	16.48	2.25 (6.953)	(-11.9, 16.40)
GSK249320 5 mg/kg vs placebo	20.00	16.48	3.52 (6.909)	(-10.5, 17.55)
GSK249320 15 mg/kg vs placebo	15.98	16.48	-0.50 (7.328)	(-15.4, 14.39)
Summary of Mixed Model Repeated Measures Analysis for Change in Grip Strength: Affected Side (All Subjects Population)				
Visit/ Comparison	Adjusted Mean		Treatment Difference (SE)	95% CI
	GSK249320	Placebo		
Visit 4 Day 30				
GSK249320 1 mg/kg vs placebo	2.64	0.98	1.66 (3.420)	(-5.33, 8.65)
GSK249320 5 mg/kg vs placebo	0.68	0.98	-0.30 (3.550)	(-7.56, 6.96)
GSK249320 15 mg/kg vs placebo	5.54	0.98	4.56 (3.534)	(-2.67, 11.78)
Visit 5 Day 60				
GSK249320 1 mg/kg vs placebo	5.21	3.15	2.05 (3.841)	(-5.78, 9.89)
GSK249320 5 mg/kg vs placebo	0.81	3.15	-2.35 (3.958)	(-10.4, 5.72)
GSK249320 15 mg/kg vs placebo	4.59	3.15	1.44 (3.978)	(-6.68, 9.55)

Visit 6 Day 90				
GSK249320 1 mg/kg vs placebo	6.21	2.75	3.46 (4.109)	(-4.94, 11.85)
GSK249320 5 mg/kg vs placebo	3.24	2.75	0.49 (4.235)	(-8.15, 9.12)
GSK249320 15 mg/kg vs placebo	3.51	2.75	0.77 (4.280)	(-7.97, 9.50)
Visit 7 Day 112				
GSK249320 1 mg/kg vs placebo	6.29	3.25	3.04 (4.205)	(-5.53, 11.61)
GSK249320 5 mg/kg vs placebo	0.67	3.25	-2.58 (4.376)	(-11.5, 6.32)
GSK249320 15 mg/kg vs placebo	6.98	3.25	3.73 (4.396)	(-5.22, 12.69)
Summary of Chi-Square Test for Modified Rankin Scale (All Subjects Population)				
Visit/ mRS Category	Placebo N=17	GSK249320 1 mg/kg N=8	GSK249320 5 mg/kg N=9	GSK249320 15 mg/kg N=8
Visit 4 Day 30				
n	14	8	9	7
0	0	0	0	0
1	2 (14)	2 (25)	1 (11)	2 (29)
2	3 (21)	1 (13)	3 (33)	0
3	3 (21)	3 (38)	3 (33)	3 (43)
4	4 (29)	2 (25)	2 (22)	2 (29)
5	2 (14)	0	0	0
Visit 6 Day 90				
n	14	8	8	6
0	0	1 (13)	1 (13)	0
1	3 (21)	1 (13)	2 (25)	2 (33)
2	5 (36)	2 (25)	2 (25)	1 (17)
3	3 (21)	4 (50)	2 (25)	0
4	3 (21)	0	1 (13)	2 (33)
5	0	0	0	1 (17)
Summary of Mixed Model Repeated Measures Analysis for Change from Baseline in NIHSS Total Score (All Subjects Population)				
Visit/ Comparison	Adjusted Mean		Treatment Difference (SE)	95% CI
	GSK249320	Placebo		
Visit 3 Day 10				
GSK249320 1 mg/kg vs placebo	-2.95	-1.61	-1.34 (0.896)	(-3.17, 0.49)
GSK249320 5 mg/kg vs placebo	-1.80	-1.61	-0.19 (0.861)	(-1.95, 1.57)
GSK249320 15 mg/kg vs placebo	-4.53	-1.61	-2.92 (0.933)	(-4.83, -1.02)
Visit 4 Day 30				
GSK249320 1 mg/kg vs placebo	-4.45	-3.75	-0.70 (0.868)	(-2.47, 1.08)
GSK249320 5 mg/kg vs placebo	-4.02	-3.75	-0.27 (0.834)	(-1.98, 1.44)
GSK249320 15 mg/kg vs placebo	-4.67	-3.75	-0.92 (0.904)	(-2.77, 0.92)
Visit 6 Day 90				
GSK249320 1 mg/kg vs placebo	-6.07	-5.04	-1.03 (1.278)	(-3.64, 1.57)
GSK249320 5 mg/kg vs placebo	-5.40	-5.04	-0.37 (1.278)	(-2.97, 2.24)
GSK249320 15 mg/kg vs placebo	-2.83	-5.04	2.21 (1.408)	(-0.66, 5.07)
Summary of Statistical Analysis for Barthel Total Score (All Subjects Population)				
Visit/ Comparison	Adjusted Mean		Treatment Difference (SE)	95% CI
	GSK249320	Placebo		
Visit 4 Day 30				
GSK249320 1 mg/kg vs placebo	86.2	66.7	19.46 (12.584)	(-6.11, 45.04)
GSK249320 5 mg/kg vs placebo	87.7	66.7	20.99 (12.131)	(-3.66, 45.64)
GSK249320 15 mg/kg vs placebo	78.5	66.7	11.79 (13.143)	(-14.9, 38.50)
Visit 6 Day 90				

GSK249320 1 mg/kg vs placebo		97.5	81.7	15.71 (9.021)	(-2.63, 34.06)
GSK249320 5 mg/kg vs placebo		93.3	81.7	11.56 (8.835)	(-6.38, 29.50)
GSK249320 15 mg/kg vs placebo		74.3	81.7	-7.49 (9.641)	(-27.1, 12.08)
Summary of Statistical Analysis for Total MoCA Score (All Subjects Population)					
Visit/ Comparison		Adjusted Mean		Treatment Difference (SE)	95% CI
		GSK249320	Placebo		
Visit 6 Day 90					
GSK249320 1 mg/kg vs placebo		21.97	22.32	-0.34 (1.849)	(-4.12, 3.43)
GSK249320 5 mg/kg vs placebo		22.15	22.32	-0.17 (1.856)	(-3.96, 3.62)
GSK249320 15 mg/kg vs placebo		21.16	22.32	-1.15 (2.037)	(-5.31, 3.01)
Summary of Statistical Analysis of Geriatric Depression Scale (GDS) (All Subjects Population)					
Visit/ Comparison		Adjusted Mean		Treatment Difference (SE)	95% CI
		GSK249320	Placebo		
Visit 6 Day 90					
GSK249320 1 mg/kg vs placebo		3.78	4.02	-0.24 (1.408)	(-3.12, 2.63)
GSK249320 5 mg/kg vs placebo		5.58	4.02	1.55 (1.347)	(-1.20, 4.30)
GSK249320 15 mg/kg vs placebo		3.97	4.02	-0.06 (1.486)	(-3.09, 2.98)
Summary of Mixed Model Repeated Measures Analysis for Change in TMS: Peak to Peak MEP by % Stimulation Level (All Subjects Population)					
Visit	Comparison	Adjusted Mean		Treatment Difference (SE)	95% CI
		GSK249320	Placebo		
Stimulation Level 100%					
Visit 4 Day 30	GSK249320 1 mg/kg vs placebo	-0.210	0.079	-0.289 (0.2639)	(-0.841, 0.264)
	GSK249320 5 mg/kg vs placebo	-0.231	0.079	-0.310 (0.2637)	(-0.862, 0.241)
	GSK249320 15 mg/kg vs placebo	-0.224	0.079	-0.303 (0.3172)	(-0.966, 0.361)
Visit 7 Day 112	GSK249320 1 mg/kg vs placebo	-0.026	-0.230	0.204 (0.1841)	(-0.184, 0.593)
	GSK249320 5 mg/kg vs placebo	-0.125	-0.230	0.105 (0.1846)	(-0.284, 0.494)
	GSK249320 15 mg/kg vs placebo	0.186	-0.230	0.416 (0.2602)	(-0.132, 0.965)
Stimulation Level 110%					
Visit 4 Day 30	GSK249320 1 mg/kg vs placebo	1.428	0.272	1.156 (0.8652)	(-0.650, 2.961)
	GSK249320 5 mg/kg vs placebo	-0.246	0.272	-0.518 (0.8324)	(-2.249, 1.213)
	GSK249320 15 mg/kg vs placebo	0.003	0.272	-0.269 (1.0383)	(-2.436, 1.898)
Visit 7 Day 112	GSK249320 1 mg/kg vs placebo	0.698	-0.108	0.806 (0.5862)	(-0.420, 2.031)
	GSK249320 5 mg/kg vs placebo	-0.115	-0.108	-0.007 (0.5640)	(-1.183, 1.168)
	GSK249320 15 mg/kg vs placebo	1.399	-0.108	1.506 (0.7570)	(-0.064, 3.077)
Stimulation Level 120%					
Visit 4 Day 30	GSK249320 1 mg/kg vs placebo	2.156	0.512	1.644 (1.2976)	(-1.056, 4.344)
	GSK249320 5 mg/kg vs placebo	0.281	0.512	-0.231 (1.1762)	(-2.681, 2.219)
	GSK249320 15 mg/kg vs placebo	0.327	0.512	-0.184 (1.4796)	(-3.279, 2.910)
Visit 7 Day 112	GSK249320 1 mg/kg vs placebo	0.956	0.334	0.622 (0.9746)	(-1.428, 2.672)
	GSK249320 5 mg/kg vs placebo	-0.268	0.334	-0.602 (0.9340)	(-2.560, 1.356)
	GSK249320 15 mg/kg vs placebo	2.396	0.334	2.063 (1.2810)	(-0.610, 4.736)
Stimulation Level 130%					
Visit 4 Day 30	GSK249320 1 mg/kg vs placebo	2.029	0.472	1.556 (1.4588)	(-1.494, 4.607)
	GSK249320 5 mg/kg vs placebo	-0.058	0.472	-0.531 (1.2336)	(-3.102, 2.041)
	GSK249320 15 mg/kg vs placebo	0.287	0.472	-0.185 (1.5697)	(-3.471, 3.101)
Visit 7 Day 112	GSK249320 1 mg/kg vs placebo	0.949	0.263	0.686 (1.2689)	(-1.996, 3.367)
	GSK249320 5 mg/kg vs placebo	-0.293	0.263	-0.556 (1.0822)	(-2.838, 1.726)
	GSK249320 15 mg/kg vs placebo	2.482	0.263	2.219 (1.4792)	(-0.884, 5.322)
Stimulation Level 140%					
Visit 4 Day 30	GSK249320 1 mg/kg vs placebo	2.201	0.569	1.631 (1.5890)	(-1.696, 4.958)
	GSK249320 5 mg/kg vs placebo	0.061	0.569	-0.508 (1.2985)	(-3.219, 2.203)

	GSK249320 15 mg/kg vs placebo	0.679	0.569	0.110 (1.6603)	(-3.369, 3.588)
Visit 7 Day 112	GSK249320 1 mg/kg vs placebo	1.051	0.199	0.852 (1.5675)	(-2.446, 4.150)
	GSK249320 5 mg/kg vs placebo	-0.159	0.199	-0.357 (1.2918)	(-3.074, 2.359)
	GSK249320 15 mg/kg vs placebo	1.884	0.199	1.686 (1.7306)	(-1.937, 5.308)

Summary of Biomarker Values (All Subjects)¹				
Treatment Group	Placebo N=17	GSK249320 1 mg/kg N=8	GSK249320 5 mg/kg N=9	GSK249320 15 mg/kg N=8
Visit 1 – Pre-dose, n	13	4	8	8
Mean (SD)	-1.021 (1.3655)	-1.224 (1.0676)	-0.978 (1.3218)	-1.624 (1.1256)
Median	-0.799	-1.132	-1.407	-1.560
Median Range	-3.00; 1.37	-2.53; -0.11	-2.41; 1.41	-3.22; -0.14
Visit 1 – 1 hr post-dose, n	13	4	8	8
Mean (SD)	-1.024 (1.203)	-0.785 (1.3917)	-1.130 (1.4363)	-1.615 (1.2312)
Median	-0.799	-0.844	-1.454	-0.968
Median Range	-3.00; 0.48	-2.41; 0.96	-2.81; 1.12	-3.51; -0.54
Visit 1 – 6 hrs post-dose, n	13	4	8	8
Mean (SD)	-0.851 (1.4014)	-1.251 (1.0449)	-0.895 (1.4683)	-1.135 (0.7006)
Median	-0.673	-1.202	-1.181	-0.955
Median Range	-2.81; 1.30	-2.53; -0.07	-2.53; 1.52	-2.04; -0.21
Visit 1 – 24 hrs post-dose, n	13	4	8	7
Mean (SD)	-1.053 (1.4309)	-1.329 (0.9649)	-0.744 (1.3523)	-1.644 (1.0244)
Median	-0.713	-1.277	-0.833	-1.897
Median Range	-3.00; 1.16	-2.53; -0.24	-2.81; 1.49	-2.81; -0.22
Visit 2, n	9	3	8	8
Mean (SD)	-1.050 (1.0039)	-1.697 (0.7264)	-0.920 (1.1960)	-1.821 (0.9974)
Median	-1.139	-1.897	-1.454	-1.579
Median Range	-2.53; 1.13	-2.30; -0.89	-2.21; 1.01	-3.51; -0.53

1. Serum levels of the S100β protein

Conclusions:

- GSK249320 was generally well tolerated in subjects with mild to moderate stroke. No major safety issues were identified in the study, and based on the available data, it was concluded there was no suggestion of systematic harm with GSK249320 treatment over placebo treatment.
- The majority of AEs were mild or moderate in intensity and there was no clear relationship between GSK249320 dose level and reporting frequency for any of the individual AEs. There were no AE reports suggestive of infusion site reactions, allergic or hypersensitivity reactions, or peripheral or central demyelination with GSK249320 treatment. There were no fatal SAEs or any AEs leading to discontinuation.
- No clinically significant trends were observed post dosing in terms of: vital signs, ECG results, and clinical laboratory parameters.
- No clinically significant trends were observed post dosing in NCT results and observed white matter changes on MRI. Additionally, there was no suggestion of peripheral or central demyelination secondary to GSK249320 treatment based on the available NCT and MRI data.
- Of the 25 subjects who were dosed with GSK249320, only 2 (8%) subjects developed transient anti-drug antibodies post Dose 1. None of the immunogenicity positive responses were associated with alterations in PK profiles or SAEs related to the investigational product.
- There was no evidence of target-mediated clearance across the dose range tested.
- While not powered to demonstrate efficacy, gait velocity data from MAG111539 suggest a trend toward benefit with GSK249320 treatment which warrants further exploration. There were no apparent trends in the PD functional and electrophysiological results that might be suggestive of a clinical worsening of those subjects who received

GSK249320.

- Detectable levels of S100 β were measured in all subject serum samples suggesting the presence of blood brain barrier leakage although no differences in S100 β levels were observed between placebo- and GSK249320-dosed subjects. No change in S100 β levels were observed over time in any of the subjects. A comparison of NIHSS Total Score at Baseline compared with S100 β serum levels demonstrated a potential trend to increased S100 β with more severe stroke.